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Endoplasmic reticulum (ER) is the first membrane compartment of secretory pathway in 
eukaryotic cells. Newly synthesized proteins are translocated into ER lumen, and they 
are screened by endoplasmic reticulum quality control (ERQC) system. Only correctly 
folded and functional proteins can be sorted out to Golgi and later membrane 
compartments. Misfolded proteins are retained in the ER and turned over by a 
mechanism conserved from yeast to human known as endoplasmic reticulum-associated 
protein degradation (ERAD). While the mammalian system is less understood, the 
ERAD mechanism in yeast is explained in more detail, and it is shown to be centered on 
two membrane associated E3 ubiquitin ligases: Hrd1p and Doa10p. Previous studies 
suggested that Hrd1p ubiquitinates misfolded luminal proteins and membrane proteins 
with luminal lesions, while Doa10p targets membrane proteins with misfolded cytosolic 
domain. But how exactly the two ERAD E3s detects these lesions remains elusive. 
 
In this thesis, I have used Saccharomyces cerevisiae as a model organism to study the 
quality control of two classes of ER luminal proteins – N-linked glycoproteins and 
non-glycosylated proteins, both of which are ERAD substrates and degraded by Hrd1p 
when misfolded. 
 
In Chapter 3 of this thesis, to study how misfolded N-linked glycoproteins are 
recognized by ERQC and ERAD, I started with analyzing two model substrates CPY* 
vii 
 
and PrA*. Both of these misfolded ER luminal proteins contain multiple N-linked 
glycans, but only one of them is necessary and sufficient for ERAD. Serial deletion 
analyses in neither CPY* nor PrA* identified ERAD determinant in the polypeptide 
primary sequences, suggesting the determinant might exist in higher order structures. I 
inspected the tertiary structure of wild type CPY and found the specific ERAD signal 
glycan is positioned on an 11-stranded β-sheet that is arranged mostly in parallel. This 
suggests that formation of the local structure adjacent the glycan is dependent on the 
overall folding of the polypeptide. Biochemical analysis of CPY* showed that the 
polypeptide region adjacent the ERAD signal glycan – termed bipartite ERAD signal, is 
tightly bound to Kar2p, a molecular chaperone in the ER lumen and essential 
component of the Hrd1p ERAD complex. Indeed the bipartite signal is as simple as a 
glycan attached to an unfolded/disordered structure. Consistent with this hypothesis, 
lesions introduced throughout CPY to specifically disrupt local structures surrounding 
non-ERAD glycans could efficiently report to ERAD through that designated glycan. 
Moreover, the position of the bipartite signal on a glycoprotein suggests a possible role 
in sensing the overall folding of the polypeptide. Normally the bipartite signal exists in 
a stable conformation buried into the tertiary structure of a folded glycoprotein to pass 
quality control. However should the protein misfold, the bipartite signal will remain 
disordered and exposed to ERQC and ERAD. 
 
In Chapter 4 of this thesis, I described the study in collaboration with Dr. Kazue 
Kanehara (experiments done by Dr. Kazue Kanehara are indicated in respective figure 
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legends) to decipher the mechanism for quality control of non-glycosylated proteins in 
the ER lumen. Similar to N-linked glycoproteins, non-glycosylated proteins also subject 
to ERQC, but the exact machinery responsible is largely unknown. In this chapter, Dr. 
Kazue Kanehara performed a comprehensive analysis to reveal the genetic requirements 
for ERAD of misfolded glycoprotein as well as non-glycosylated proteins. Although 
both depend on Hrd1p, glycoproteins require additional luminal factors for their 
degradation compared to non-glycosylated proteins. By systematic deleting primary 
sequence of non-glycosylated PrA* variant, I discovered a signal in the polypeptide 
chain both necessary and sufficient for its degradation, suggesting the 
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1.1. General introduction 
 
1.1.1. Quality control in the cell 
 
All free living organisms are made of cells, and in every single cell proteins carry out 
most cellular functions. Life depends on cells, and on countless proteins to fold 
correctly and function as they are designed to. Cells make proteins in a very similar 
way as factories manufacture their various products. As factories sometimes make 
faulty products, cells also occasionally produce misfolded and malfunctioning 
proteins that could cause problems. In order to alleviate potential problems, cells use 
specialized processes to promote correctly folded proteins, and most importantly, to 
dispose of misfolded proteins, like factories do to their faulty products. This 
specialized process is termed protein folding quality control. 
 
Quality control is of vital importance to all organisms, from single cell to higher 
eukaryotes. There are plenty of serious human diseases caused, either directly or 
indirectly, by defects in quality control system. For example, cystic fibrosis, a severe 
genetic disorder, is caused by the rapid turnover of mutated cystic fibrosis 
transmembrane conductance regulator (CFTR) (Ward et al., 1995). And defects in 
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coping with excess misfolded proteins could result in diabetes and neurodegenerative 
disorders such as Alzheimer’s disease and Parkinson’s disease (Yoshida, 2007). 
Therefore, understanding the basic principles underlying cellular quality control 
mechanism could lead to promising treatments or even cures for those diseases. 
 
1.1.2. The secretory pathway 
 
The endoplasmic reticulum (ER) is a major site of protein synthesis in eukaryotic 
cells, and it is the first membrane compartment of secretory pathway. Proteins are 
destined for the secretory pathway by signal sequences, short hydrophobic segments 
at the very N-terminus (Milstein et al., 1972). Polypeptides are synthesized first in the 
cytosol by ribosomes, and transported through or integrated into ER membrane 
through the Sec61p translocon complex (Rapoport, 2007). This process is termed 
translocation, and it has two different routes, co-translational or post-translational 
translocation, which is dictated by the hydrophobicity of the signal sequence (Ng et 
al., 1996). In co-translational translocation, while a polypeptide is still being 
synthesized by the ribosome, its signal sequence is recognized by signal-recognition 
particle (SRP) and targeted to the ER membrane by SRP receptor (Halic and 
Beckmann, 2005). In post-translational mode, only after the synthesis of the 
polypeptide is completed and it’s released from ribosome can it be targeted to the ER 
membrane, and this process occurs independently of SRP and its receptor but requires 
additional membrane complex Sec62p-Sec63p (Deshaies et al., 1991; Huber et al., 
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2005a; Huber et al., 2005b; Panzner et al., 1995). In either mode, the diameter of the 
Sec61p translocon pore limits the translocating polypeptides with α-helixes at most, 
and no tertiary structure can be accommodated (Bostina et al., 2005; Haider et al., 
2006; Kowarik et al., 2002; Saparov et al., 2007; Tian and Andricioaei, 2006; Van den 
Berg et al., 2004). This means polypeptides enter the ER lumen largely unfolded, 
therefore the ER becomes a site in the cell where major folding events occur. 
 
Inside the ER lumen, a wide range of methods are provided to assist the folding of the 
newly translocated polypeptides. Covalent modifications such as N-linked 
oligosaccharides are added while the polypeptides are still in the translocon (Helenius 
and Aebi, 2004). ER resident molecular chaperones directly bind the folding 
polypeptide to prevent aggregation and promote their native conformation (Buck et al., 
2007). In the oxidative environment of the ER lumen, free cysteine pairs on the 
polypeptide are prone to form disulfide bonds often indispensible for the complete 
folding process (Frand and Kaiser, 1998). Eventually, correctly folded and functional 
proteins are packed inside COPII vesicles and transported to Golgi and later 
membrane compartments of the secretory pathway (Barlowe, 2003). 
 
1.1.3. Quality control in the ER 
 
The high throughput assembly line of ER protein synthesis will inevitably encounter a 
population of proteins that fail to acquire their native structure. The ER must employ 
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a censoring system to search and detain these misfolded ones, otherwise allowing the 
malfunctioning proteins to slip through would be detrimental to the overall safety of 
the cell, sometime even the whole organism. More than three decades ago, evidence 
suggesting the existence of such system was already discovered. A mutant form of 
α1-antitrypsin causing severe emphasema and liver disease in humans was retained in 
the ER of liver cells (Hercz et al., 1978). More evidences were gathered from the 
study of another pathogen influenza virus hemagglutinin (HA). Correctly folded HA 
subunits assembled into oligomers can exit the ER (Gething et al., 1986), whereas the 
misfolded species are bound to ER resident chaperon BiP (immunoglobulin heavy 
chain binding protein) and retained (Hurtley et al., 1989). Similar results were found 
in the study on vesicular stomatitis virus G protein, and it is during that time de Silva 
and coworkers first gave this system its name: endoplasmic reticulum quality control 
(ERQC) (de Silva et al., 1990). Now it is established that ERQC is a surveillance 
mechanism, conserved in all eukaryotes, that monitors folding status of newly 
synthesized secretory proteins entering the ER lumen. Moreover, after ERQC singles 
out the misfolded proteins, it also delivers them to a downstream destruction 
mechanism termed ER-associated protein degradation (ERAD). 
 
1.1.4. Advantages for studying quality control in yeast 
 
Conserved among all eukaryotes, ERQC and ERAD have been extensively studied in 






Figure 1.1. Saccharomyces cerevisiae under DIC microscopy 
Saccharomyces cerevisiae is a unicellular fungus, generally round in shape and 5-10 
μm in diameter, with a doubling time about 2 hours at 30℃. Its reproduction process 
starts with the daughter cell emerging as a “bud” from the surface of the mother cell, 
hence the common name “budding yeast”. The subsequent asymmetric cell division 




is a unicellular fungus (Figure 1.1). Compared with the mammalians, budding yeast 
has a much smaller genome: only 6,000 genes in 12 Mbp, while human has 30,000 
genes. Nevertheless it contains all the basic components of ERQC and ERAD, 
offering a system to be studied with less complexity. Moreover, the advanced 
techniques in yeast genetics, as well as the availability of many mutant strains, makes 
the study in all much easier. 
 
1.2. ER quality control machinery 
 
1.2.1. Role of N-linked glycosylation in ERQC 
 
N-linked glycoproteins constitute majority of secretory proteins among all eukaryotes. 
The N-linked oligosaccharides are presynthesized on the ER membrane and then 
added to proteins all at once (Helenius and Aebi, 2004). The core structure, 
Glc3Man9GlcNAc2, is composed of three glucoses, nine mannoses, and two 
N-acetylglucosamines (Figure 1.2) (Helenius and Aebi, 2004). Synthesis of the core 
oligosaccharide starts first on the cytosolic face with a lipid linkage to the ER 
membrane. During the process, an enzyme named Rft1p flips the lipid-linked 
oligocaccharide intermediate into the luminal face of the ER membrane (Helenius et 
al., 2002), and the synthesis continues. At the last step, an enzyme complex 
collectively called oligosaccharyltransferase (OST) transfers the lipid-linked final 




Figure 1.2. Synthesis of N-linked oligosaccharide and its transfer to a polypeptide 
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Asn-X-Ser/Thr consensus site of the polypeptide (Burda et al., 1999). 
 
One intriguing observation was made: although the glycan is first added to the 
polypeptide as Glc3Man9GlcNAc2, protein leaves the ER all bears N-glycans as 
Man8GlcNAc2 with all three glucose and one mannose residues trimmed away 
(Kornfeld and Kornfeld, 1985). Therefore naturally came the question: why almost all 
eukaryotic cells, from yeast to human, have evolved this highly sophisticated 
procedure to synthesize a large oligosaccharide, only to trim it down almost right 
away in the very same compartment? The logic behind this seemingly energy-wasting 
effort is that each trimming product reports to the ER quality control system about the 
folding state of the nascent polypeptide chain. 
 
1.2.1.1. The calnexin/calreticulin cycle 
 
As soon as the core Glc3Man9GlcNAc2 oligosaccharide is attached to the emerging 
polypeptide in the ER lumen, the protein enters the calnexin/calreticulin cycle. 
Calnexin (CNX) is a type I transmembrane protein, while calreticulin (CRT) is a 
luminal protein, and together these two lectins act as the first stage of the ER quality 
control system (Caramelo and Parodi, 2008; Williams, 2006). 
 
Association of the nascent polypeptide chain with the CNX/CRT requires the 
sequential trimming of the outmost two glucose residues on branch A of the glycan by 
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glucosidase I and glucosidase II (GI and GII) (Deprez et al., 2005; Hebert et al., 1995) 
(Figure 1.3). Interacting with lectins CNX/CRT through the trimmed 
Glc1Man9GlcNAc2 oligosaccharide protects the emerging polypeptide from forming 
aberrant aggregates with other unstructured chains. Thus this association gives the 
nascent proteins longer time and better chance to achieve their own native structure. 
Besides removing the second glucose residue, GII is also able to cleave the third one, 
and this action releases the Man9GlcNAc2 oligosaccharide bearing polypeptide from 
CNX/CRT. However, if at this time the polypeptide has not formed a stable structure, 
it is allowed to re-associate with CNX/CRT for another folding attempt, and the 
re-entry permit is issued by the enzyme glucosyltransferase (GT) (Caramelo et al., 
2004; Pearse et al., 2008; Trombetta et al., 1991). GT adds one glucose residue back 
to branch A of the glycan, thus sending it back into the CNX/CRT cycle (Labriola et 
al., 1995). The collective de- and re-glucosylation actions of GI, GII and GT ensure 
the nascent proteins are retained by CNX/CRT cycle until they are deemed mature 
enough to exit, and then other molecular chaperones come into play. 
 
Although the CNX/CRT lectins are absent from the genome of S. cerevisiae, current 
knowledge indicates that the use of N-linked oligosaccharide as a signal reporting to 
ERQC is conserved among all eukaryotes. In fact, the lack of CNX/CRT cycle in 
yeast renders later stages of quality control (for example the “mannose timer” 
hypothesis discussed below) in this organism to be more prominent, hence more 







Figure 1.3. Regulation of calnexin/calreticulin cycle by de-glucosylation and re-glucosylation enzymes 
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Figure 1.3. Regulation of calnexin/calreticulin cycle by de-glucosylation and 
re-glucosylation enzymes 
GI and GII sequentially remove the first two glucose residues from branch A, the 
resulting polypeptide bearing Glc1Man9GlcNAc2 oligosaccharide enters the 
calnexin/calreticulin cycle. After GII removes the last glucose residue, the polypeptide 
with Man9GlcNAc2 exits the cycle, but GT is able to add back the glucose residue thus 
allowing the polypeptide for another round of folding attempt in the cycle. 
12 
 
1.2.1.2. “Mannose timer” hypothesis 
 
After the glucose residues are removed from the core oligosaccharide, the nascent 
polypeptide with Man9GlcNAc2 glycans emerging from the translocon in yeast (or 
after the polypeptide chain is released from CNX/CRT cycle in mammalian cells), it is 
subject to another important ER quality control process. Similar as CNX/CRT cycle, 
the structure of the oligosaccharide is used as a signal in this process, and three ER 
luminal proteins sequentially participate in presenting and recognizing this N-glycan 
signal: Mns1p (α-mannosidase I), Htm1p (homologous to mannosidase I) and Yos9p 
(yeast osteosarcoma 9). 
 
Mns1p is the first enzyme to trim the Man9GlcNAc2 oligosaccharides. It removes 
from branch B an α1,2-linked mannose residue, making the glycan Man8GlcNAc2  
(Jelinek-Kelly and Herscovics, 1988) (Figure 1.4). When nascent glycoproteins 
entering the ER lumen are trying to fold, they are at the same time subject to the 
processing by Mns1p. Compared with GI and GII, Mns1p cleaves glycans with 
relatively slow kinetics therefore the glycoproteins are given sufficient time to fold 
(Jakob et al., 1998a). So the “mannosidase timer” hypothesis was proposed. By the 
time Man9GlcNAc2 oligosaccharides are trimmed down to Man8GlcNAc2, it also 
serves as a signal to ERQC that the glycoprotein has expired its folding time window, 






Figure 1.4. Mannosidase-lectin signal-receptor system 
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Figure 1.4. Mannosidase-lectin signal-receptor system 
The Man9GlcNAc2 oligosaccharides on nascent glycoproteins are trimmed further 
down to Man8GlcNAc2 by Mns1p. The folding state of the glycoprotein is then 
examined by ER quality control mechanism. Those deemed as irreversibly misfolded, 
will have another mannose residue cleaved by the Htm1p/PDI complex. The end 
product, Man7GlcNAc2, exposes an α1,6-linked mannose residue in its structure. 
Lectin receptor Yos9p recognizes this mannose residue with the specific α1,6-linkage, 





The other two luminal factors in this cascade are Htm1p and Yos9p. Htm1 was first 
identified as a mannosidase-like protein, because it has 40% sequence similarity to 
yeast mannosidase but lacks the key cysteine residues essential for α1,2-mannosidase 
activity (Jakob et al., 2001; Nakatsukasa et al., 2001), and Yos9p was discovered as a 
receptor lectin (Bhamidipati et al., 2005; Kim et al., 2005; Szathmary et al., 2005). 
Little is known about how Htm1p and Yos9p participate in ERQC except that they are 
both required for the degradation of misfolded glycoproteins by ERAD, and Htm1p 
was originally proposed to act as a lectin-like receptor for ERAD (Hosokawa et al., 
2003; Molinari et al., 2003). However, Htm1p’s role as a bona fide α1,2-mannosidase 
in vivo was recently reinstated (Clerc et al., 2009). The study has also shown that GI, 
GII and Mns1 trimming is a prerequisite for Htm1p function. Although it follows 
immediately after Mns1p, Htm1p only targets misfolded glycoproteins while leaving 
the correctly folded ones untouched (Jakob et al., 2001; Nakatsukasa et al., 2001). 
Htm1p cleaves off the first mannose residue from branch C, resulting in a 
Man7GlcNAc2 glycan (Figure 1.4). This trimming step exposes an α1,6-linked 
mannose residue, which exhibits significantly high binding affinity for the ER lectin 
Yos9p (Quan et al., 2008). Yos9p, which is in direct association with the ERAD 
machinery, acts as a proofreading receptor lectin. It binds misfolded glycoproteins 
directly through the α1,6-mannose of Man7GlcNAc2 glycans, and delivers substrates 
to ERAD. 
 
It is worth noting that ER mannosidases (Mns1p and Htm1p) work sequentially to 
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create the ligand (Man7GlcNAc2 glycans) for recognition by the receptor lectin Yos9p, 
indicating the regulation of ERQC also follows the canonical ligand-receptor model as 
many other cell signaling pathways. 
 
1.2.2. ER molecular chaperones 
 
Apart from mannosidases and lectins, molecular chaperones also play an important 
role in ERQC after the nascent polypeptides enter the ER lumen. To date, BiP and PDI 
(and their co-factors) are the two best studied ER luminal molecular chaperones, both 




BiP is also known as GRP78 (glucose-regulated protein 78), because it was identified 
separately both as a protein that binds immunoglobulin heavy chain (Haas and Wabl, 
1983), and as a protein whose synthesis can be increased by glucose starvation (Shiu 
et al., 1977). Later they are actually found to be identical to each other, and more 
interestingly, this 78 kD ER luminal protein belongs to the molecular chaperone 
Hsp70 family (Munro and Pelham, 1986). 
 
As all members of the Hsp70 family chaperones, BiP and its yeast homolog Kar2p are 
composed of an N-terminal ATPase domain, a peptide binding domain and a 
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C-terminal lid domain (Flaherty et al., 1990; Zhu et al., 1996). The peptide binding 
domain of BiP/Kar2p has a higher affinity for polypeptide with hydrophobic segments 
in an extended comformation (Blond-Elguindi et al., 1993). And the peptide binding 
function depends on its ATPase domain which can be activated by two Hsp40 family 
co-chaperones Scj1p and Jem1p (Nishikawa et al., 2001; Silberstein et al., 1998). The 
ATP-bound BiP/Kar2p has low affinity for the polypeptide substrate, whereas upon 
Scj1p and Jem1p binding and activating the ATPase domain, the resulting ADP-bound 
BiP/Kar2p exhibits high affinity for its substrate (McCarty et al., 1995; Russell et al., 
1999). The exchange of ADP to ATP triggers the release of the substrate and frees 
BiP/Kar2p to engage other polypeptides and assist their folding (Gisler et al., 1998; 
Mayer et al., 2000b). Recent study has indicated Lhs1p, another ER lumen Hsp70 
family chaperone, acts as the nucleotide exchanging factor (NEF) for BiP/Kar2p, 
while BiP/Kar2p acts as the ATPase activating protein for Lhs1p (Lin et al., 1993; 
Steel et al., 2004). In this way BiP/Kar2p cycles to bind nascent polypeptide in the ER 
and ensure their correct folding. 
 
Apart from function as a chaperone to assist protein folding in the ER, BiP/Kar2p is 
also required for both co- and post-translational translocation of proteins into the ER 
lumen and essential for cell viability, although this process does not require ATP 
(Brodsky et al., 1995; Hamman et al., 1998; Matlack et al., 1999). Moreover, kar2-1, 
a yeast strain harboring a mutation in the peptide binding domain of Kar2p, exhibits 
no severe growth defect but only impaired ERAD machinery, suggesting the 
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chaperone function of Kar2p can be separated from its essential house-keeping 




Protein disulfide isomerase (PDI) is a 110 kD protein expressed abundantly in the ER 
lumen (Goldberger et al., 1963). It belongs to thiol oxidoreductase class of proteins 
that participates in ERQC by rearranging aberrant disulfide-bonds in folding 
polypeptide (Jordan and Gibbins, 2006; Nishikawa et al., 2005; Tu and Weissman, 
2004). Crystal structure of yeast PDI indicates the protein has a “U” shape: a central 
hydrophobic groove with two CxxC catalytic sites located separately on each arm 
(Tian et al., 2006). Information from its crystal structure, together with earlier studies 
(Cai et al., 1994; Darby et al., 1998; Koivunen et al., 1999; Song and Wang, 1995), 
suggests PDI binds hydrophobic stretches of proteins in the folding process in its 
groove, breaks the wrong disulfide-bonds and catalyzes the formation of correct ones. 
After this reaction, PDI can be recycled for the next round of substrates by Ero1p (ER 
oxidation 1), which recharges PDI’s catalytic sites to an oxidized state (Frand and 
Kaiser, 1999; Tu et al., 2000). 
 
Both being ER lumen chaperones, BiP and PDI are reported to cooperate in assisting 
the folding of nascent polypeptides (Mayer et al., 2000a). In an in vitro folding of 
antibody Fab fragment, BiP can bind the antibody chain and expose it so that PDI is 
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able to access the cysteine residue side chains. Without BiP, the unfolded polypeptide 
chain aggregates rapidly therefore PDI is unable to rearrange the disulfide bond 
necessary for its folding. Althought this study was carried out in vitro, it has provided 
valuable insights into how different subsets of molecular chaperones synergize in ER 
quality control within the cells. 
 
Besides cooperation with BiP/Kar2p, a recent study indicated PDI is also in direct 
association with Htm1 (Sakoh-Nakatogawa et al., 2009). PDI interacts with Htm1p 
both non-covalently and through intermolecular disulfide bond. More interestingly, 
the intermolecular disulfide bond in turn triggers an intramolecular disulfide bond 
within the mannosidase homology domain of Htm1p, which is essential for its 
function in ERQC and ERAD. This interaction persists even after the activation of 
Htm1p, suggesting PDI is more than just a folding chaperone for Htm1p but a stable 
and essential partner of the ER mannosidase (Figure 1.4). The functional association 
between the two different subsets of ERQC components further strengthens the idea 
that ERQC is a highly regulated mechanism dependent on not only a variety of 
components but also the interplay among them. 
 
1.3. ER-associated protein degradation 
 
All the efforts ERQC puts in to retain misfolded and malfunctioning proteins is to 
prevent them from trafficking out of the ER and messing up normal functions 
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elsewhere. But the accumulation of misfolded proteins could also be problematic to 
the ER itself, making the removal of them critical. Therefore the cells introduced 
another set of mechanism to deal with proteins deemed terminally misfolded by 
ERQC. The misfolded proteins are first extracted out of the ER by a transmembrane 
complex - a process called retro-translocation. On the cytosolic face of the ER 
membrane, the misfolded protein is poly-ubiquitinated and degraded by the 26S 
proteasome. This machinery is conserved from yeast to human, and collectively it is 
termed the ER-associated protein degradation (ERAD). 
 
1.3.1. ERAD depends on ubiquitin-proteasome system 
 
Evidences suggesting the linkage between ERAD and the ubiquitin-proteasome 
system (UPS) came from the analysis on several ERQC substrate proteins, including 
CPY* and PrA* (mutant variants of vacuolar proteases), sec61-2 (mutant Sec61 
translocon subunit), HMGR (HMG-CoA reductase) and CFTRΔF508 (mutant CFTR). 
All of these misfolded proteins are degraded by the 26S proteasome (Biederer et al., 
1996; Finger et al., 1993; Hampton and Rine, 1994; Sommer and Jentsch, 1993; Ward 
et al., 1995). Later on, a screen designed to look for genes involved in ERAD, 
identified the HRD (HMG-CoA reductase degradation) genes Hrd1p, Hrd2p and 
Hrd3p (Hampton et al., 1996). Hrd1p is an ER E3 ubiquitin ligase (discussed in 
section 1.4.2) while Hrd3p is its partner, and Hrd2p (also know as Rpn1p) is a subunit 
of the 19S regulatory particle of the 26S proteasome. All of the three genes are 
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components of the UPS. This finding proves that the UPS serves as a functional 
component of ERAD machinery to ubiquitinate and degrade misfolded proteins in the 
ER. 
 
With the final destination of misfolded proteins known, another question remained. 
Although the ERQC substrates are detected and retained in the ER, they are 
eventually degraded in the cytosol. What is the mechanism to extract them out of the 
ER? The answer is the AAA-ATPase family, which was already shown to be 
responsible for extracting and degrading membrane proteins in bacteria and 
mitochondria (Kihara et al., 1999; Leonhard et al., 2000). In fact the AAA-ATPase 
Cdc48p in yeast and p97 in mammals was soon found to be required for the export of 
misfolded ER proteins into the cytosol and their subsequent degradation by the UPS 
(Jarosch et al., 2002; Rabinovich et al., 2002; Ye et al., 2001). A functional 
AAA-ATPase complex is composed of a homo-hexamer of p97/Cdc48p, and two 
co-factors Npl4p and Ufd1p (Meyer et al., 2000; Pye et al., 2007). Docked on the 
cytosolic face of the ER membrane by membrane protein Ubx2p (Neuber et al., 2005; 
Schuberth and Buchberger, 2005; Schuberth et al., 2004), the AAA-ATPase complex 
pulls polypeptides out of the ER membrane through a retro-translocon of unknown 
identity for most substrates (discussed in section 1.4.2.1), and delivers them to the 
26S proteasome for degradation. 
 




Ubiquitination is an essential function that regulates multiple biological processes in 
all eukaryotic cells. In ERAD, before the substrates can be committed to the 26S 
proteasome, they first need to be poly-ubiquitinated. Ubiquitination process is a chain 
of reactions catalyzed by three sets of enzymes: ubiquitin-activating enzyme (E1), 
ubiquitin-conjugating enzymes (E2) and ubiquitin ligase (E3) (Pickart, 2001). First, 
E1 activates ubiquitin, a small protein of only 8.5 kDa, through hydrolyzing ATP and 
forms a thioester linkage carboxyl group of ubiquitin and the E1 cysteine sulfhydryl 
group. Second, the activated ubiquitin is transferred from E1 to the cysteine residue 
on the active site of E2. At the final step, the E3 ligase attaches ubiquitin to a lysine 
residue of the target protein. In general, the E1-E2-E3 cascade is centered on the E3 
ligase, and E3 often functions as substrate recognition module of the system and 
interact with both E2 and the substrate. Ubiquitination process of ERAD follows the 
same cascade, with components organized separately around two E3s integrated in the 
ER membrane: Hrd1p (HMG-CoA reductase degradation) and Doa10p (degradation 
of alpha2). These two E3s each covers distinct classes of misfolded proteins, and 
together they recognize a broad range of substrates, making a proficient ERAD 
system. 
 
1.3.2.1. The Hrd1p complex 
 
The Hrd1p complex is composed of the transmembrane ubiquitin ligase Hrd1 and its 
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partner Hrd3p, two other transmembrane proteins Usa1p and Der1p. On the cytosolic 
face of the complex, ubiquitin-conjugating enzyme Ubc7p is docked on the membrane 
through anchor protein Cue1p, and the Cdc48p-Ufd1p-Npl4p AAA-ATPase complex 
is also associated with the complex through membrane anchor Ubx2p (Carvalho et al., 
2006; Denic et al., 2006) (Figure 1.5A). 
 
Hrd1p, also known as Der3p (degradation in the ER), was identified in two 
independent screens designed to find ERAD related genes. It was found to be 
involved in the degradation of two different classes of substrates: membrane proteins 
HMG-CoA reductase and sec61-2 and misfolded luminal protein CPY* (Bordallo et 
al., 1998; Hampton et al., 1996). Hrd1p contains six transmembrane spans and a 
RING-H2 (Really Interesting New Gene) domain essential for its E3 activity located 
on the cytosolic face (Bays et al., 2001a; Deak and Wolf, 2001). Hrd3p, co-factor of 
Hrd1p, contains a large luminal domain bearing tetratricopeptide repeats (TPR) 
necessary for ERAD and for docking of luminal lectin receptor Yos9p (Gauss et al., 
2006a). Hrd1p and Hrd3p form a stable heterodimer, and the interaction stabilizes 
Hrd1p itself (Gauss et al., 2006b). Without Hrd3p, excess Hrd1p will undergo 
self-degradation, in order to limit the level of uncomplexed E3 (Gardner et al., 2000). 
 
The ability of Hrd1p complex to degrade different class of substrates can be attributed 
to the modulation of its co-factors Yos9p, Der1p and Usa1p. For misfolded luminal 




Figure 1.5. Organization of the Hrd1 and Doa10 E3 complexes for ERAD 
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Figure 1.5. Organization of the Hrd1p and Doa10p E3 complexes for ERAD. 
A) Illustration of the Hrd1p complex. Lectin receptor Yos9p is in direct interaction 
with Hrd3p, a co-factor of Hrd1p E3 ligase. Cytosolic E3 conjugating enzyme Ubc7p 
is docked to the ER membrane through Cue1p. Sec61p has been suggested to act as 
the retrotranslocon for some of the Hrd1p complex substrates (see text for details). 
B) Illustration of the Doa10p complex. Ubc7p is docked to the membrane through 
Cue1p, same as in Hrd1p complex. Identity of the retrotranslocon utilized by the 
Doa10p complex is unknown. Ubx2p recruits the Cdc48p-Ufd1p-Npl4p AAA-ATPase 
complex to both Doa10p and Hrd1p complex, to provide mechanical force to extract 




members is required. First, Yos9p receives the glycoprotein substrates deemed 
terminally misfolded by ERQC from ER mannosidases Mns1p and Htm1p. By 
interacting with the luminal domain of Hrd3p, Yos9p acts as a receptor lectin and 
delivers the glycoprotein substrates directly to the Hrd1p complex (Carvalho et al., 
2006). The substrate is then extracted by Cdc48p-Ufd1p-Npl4p AAA-ATPase 
complex through the retro-translocon, and degraded in the cytosol by the 26S 
proteasome (Figure 1.6). Although several candidates have been proposed, the 
identity of the retro-translocon is still at debate. Derlin-1, the mammalian homologue 
of Der1p, can be crosslinked with substrate during retro-translocation, suggesting that 
it might be a component of ERAD retro-translocon (Lilley and Ploegh, 2004; 
Wahlman et al., 2007). However, Wolf and coworkers recently found in yeast that at 
least for luminal substrates like CPY*, the core component of translocon complex 
Sec61p also channels the retro-translocation process for the Hrd1p complex (Finke et 
al., 1996; Schafer and Wolf, 2009). 
 
Another class of substrates going through the Hrd1p complex is misfolded membrane 
proteins such as HMGR, sec61-2 and the mutated ATP-binding cassette transporter 
Pdr5* (Plemper et al., 1998). Although requiring all other common co-factors 
including Cue1p, Ubc7p, Ubx2p and the Cdc48p-Ufd1p-Npl4p AAA-ATPase 
complex, ERAD of membrane substrates is independent of Yos9p, Der1p or Usa1p 
(Carvalho et al., 2006; Taxis et al., 2003). Hrd3p is still a necessary partner of Hrd1p 







Figure 1.6. ERAD of luminal substrates by the Hrd1 complex 
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Figure 1.6. ERAD of luminal substrates by the Hrd1p complex 
Luminal glycoprotein substrates are recognized by the Hrd1p complex and its 
co-factors. Yos9p binds the misfolded glycoprotein (shown as red line) through the 
Man7GlcNAc2 glycan, and delivers it to the Hrd1p-Hrd3p complex, coupled with 
Sec61p as the retrotranslocon. The polypeptide is in turn extracted through the Sec61p 
pore by the Cdc48p-Ufd1p-Npl4p AAA-ATPase complex, and ubiquitinated (shown 
as brown hexagon) at the cytosolic side by Ubc7p E2 conjugating enzyme and Hrd1p 
E3 ligase. The poly-ubiquitinated substrate is eventually degraded by the 26S 
proteasome. Only components participating in each step are colored and labeled the 




recognition step. Instead, site-directed mutagenesis study has suggested that the E3 
ubiquitin ligase Hrd1p itself is very likely to recognize the misfolded membrane 
proteins directly through its multi-spanning transmembrane domains (Sato et al., 2009) 
(Figure 1.7). The retro-translocon component for extracting membrane substrates is 
still unclear to date. Even though Sec61p has been reported to channel this process for 
luminal substrates, there is no evidence suggesting it perform the same function for 
membrane substrates. 
 
Comparing the components required by the Hrd1p complex to degrade luminal 
substrates and membrane substrates, it appears Hrd1p-Hrd3p heterodimer first recruits 
essential factors (Cue1p, Ubc7p, Ubx2p and Cdc48p-Ufd1p-Npl4p AAA-ATPase 
complex) to form a minimum functional ubiquitin-proteasome system. This core 
complex is inherently capable of recognizing and degrading misfolded membrane 
proteins. Additional factors (Yos9p, Der1p, Usa1p and Sec61p) are recruited, and they 
form a functional module to expand the substrate pool of the Hrd1p complex into the 
ER lumen. Recent studies provided important insights into how the function of Hrd1p 
complex is regulated by one of its co-factors Usa1p (Carroll and Hampton, 2009; 
Horn et al., 2009; Kim et al., 2009). Usa1p is predicted to be an ER membrane protein 
with two transmembrane segments and both its N and C termini exposed in the 
cytosole. The N and C termini were found to bind Hrd1p and Der1p respectively, 
providing the bridge linking the two. More interestingly, Usa1p binding induces 







Figure 1.7. ERAD of membrane substrates by the Hrd1 complex 
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Figure 1.7. ERAD of membrane substrates by the Hrd1p complex 
Misfolded membrane substrates are recognized directly by the multi-spanning 
transmembrane domain of Hrd1p. The polypeptide is then extracted through a yet 
unknown retrotranslocon, possibly Hrd1p itself. Substrates are then poly-ubiquitinated 
by Ubc7p and Hrd1p, and degraded by the 26S proteasome in the cytosol. Only 
components participating in each step are colored and labeled the same as in Figure 




excess uncomplexed E3 (Gardner et al., 2000). Besides ligase stability control the 
N-terminus of Usa1p is also required for the ubiquitination and degradation of luminal 
substrate CPY*. 
 
1.3.2.2. The Doa10p complex 
 
The other ERAD complex in yeast is organized around Doa10p (Carvalho et al., 2006; 
Vashist and Ng, 2004). Doa10p was first identified as a gene essential for the 
proteasomal degradation of soluble transcription factor Matα2 in a Deg1-degron 
dependent fashion (Swanson et al., 2001). Similar to Hrd1p, Doa10p is also a 
multi-spanning tramsmembrane E3 ubiquitin ligase, and its activity is dependent on 
its RING finger on the cytosolic side (Kreft et al., 2006). But compared with the 
Hrd1p complex, the Doa10p complex has relatively simple architecture: Ubc6p and 
Ubc7p E2 conjugating enzymes docked on the ER membrane via Cue1p, and 
AAA-ATPase Cdc48p complex via Ubx2p (Figure 1.4B).  
 
The absence of luminal co-factors from the Doa10p complex has restricted its 
substrate recognition range, and indeed the complex targets a distinct class of ER 
substrate proteins from its neighbor Hrd1p. It is reported to act prior to Hrd1p, and 
detect misfolded membrane proteins, including its own component Ubc6p, mutant 
plasma membrane H+-ATPase Pma1-D378N and mutant α-factor transporter 







Figure 1.8. ERAD of membrane substrates by the Doa10 complex 
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Figure 1.8. ERAD of membrane substrates by the Doa10p complex 
Membrane substrates with cytosolic lesions are recognized by the Doa10p complex. 
The exact mechanism of Doa10p-substrate interaction, as well as the identity of the 
retrotranslocon, is yet unknown. Same as the Hrd1p complex, the 
Cdc48p-Ufd1p-Npl4p AAA-ATPase complex provides the mechanical force to extract 
the substrate out of the ER membrane. Substrates are then poly-ubiquitinated by 
Ubc7p and Doa10p, and degraded by the 26S proteasome in the cytosol. Only 
components participating in each step are colored and labeled the same as in Figure 
1.5B, irrelevant components are in grey color. 
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However, neither of the proposed retro-translocon component, Sec61p or Der1p, are 
required for the degradation of Ubc6p and Ste6-166p, suggesting Doa10p probably 
employs distinct mechanism for retro-translocation of its substrates (Figure 1.8). 
 
1.3.2.3. Mammalian ERAD complexes 
 
Compared with the two ERAD pathways in yeast, the mammalian system is 
functionally conserved but the organization of the E3 complex is more diverse. Two 
mammalian homologues of Hrd1p were identified, HRD1/synoviolin and gp78 (Chen 
et al., 2006; Fang et al., 2001; Kikkert et al., 2004). Both of these membrane E3s were 
found to ubiquitinate membrane ERAD substrates like HMG-CoA and T-cell receptor 
subunits CD3-δ and TCR-α. Similar to its yeast counterpart, HRD1 recruits SEL1L 
(mammalian Hrd3p) to function as an membrane E3 complex to dislocate class I 
major histocompatibility complex (MHC) heavy chains (HCs) out of the ER (Mueller 
et al., 2008; Mueller et al., 2006). Although the E2 conjugating enzyme working with 
HRD1 has yet to be identified in vivo, Ube2g2 (mammalian Ubc7) was shown to be 
able to perform as surrogating E2 in vitro (Kikkert et al., 2004). Unlike HRD1, the 
other membrane E3 gp78 functions independently of SEL1L, but it can recruit the E2 
conjugating enzyme Ube2g2 directly (Chen et al., 2006; Li et al., 2007). 
 
In mammalian system, TEB4 is considered as a Doa10 ortholog with similar 
membrane topology and a RING-finger ubiquitin ligase domain (Hassink et al., 2005; 
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Kreft et al., 2006). But unlike Doa10 complex with a relatively large client pool, no 
cellular substrate was described so far for TEB4. Instead, TEB4 was found to promote 
self-polyubiquitination and degradation in vitro using Ube2g2 as E2 conjugating 
enzyme. 
 
1.4. Objectives of the thesis 
 
My thesis focuses on quality control process of ER luminal proteins, specifically the 
mechanism for their recognition ERQC as misfolded proteins. As discussed in section 
1.3, the “mannose timer” model described how the ER mannosidases and lectins 
convey the ERAD signal by modifying structure of N-linked oligosaccharides, but 
there are still some unanswered questions. 
 
First, in the current model, Mns1 and Htm1 sequentially trim the N-glycan to produce 
Man7GlcNAc2 core structure to mark misfolded proteins (Clerc et al., 2009). But the 
fact that folded proteins exiting ER all bearing Man8GlcNAc2 indicates they have 
been spared by Htm1p. Therefore although Mns1p and Htm1p are both ER 
mannosidases, their substrates differ. Mns1p acts ubiquitously on all glycoproteins 
entering the ER lumen, whereas Htm1p only modifies those still misfolded after their 
folding time window expires. These observations strongly suggest that the actual 
evaluation of foldedness occurs at Htm1p. What is the mechanism behind by which 




Second, analyses of the model substrates CPY* and PrA* demonstrated that for 
proteins with multiple N-glycosylation sites, only a single, specific glycan can signal 
ERAD (Kostova and Wolf, 2005; Spear and Ng, 2005). This suggested the 
requirement of additional determinants encoded in the polypeptide chain to specify 
that particular N-glycan. Characterizing the nature of this second determinant besides 
glycan structure will help us understand the mechanism of Htm1p-dependent substrate 
recognition, in another word, the criteria ERQC enforces on glycoprotein folding. 
 
Third, non-glycosylated proteins also occupy a considerable population among all 
secretory proteins trafficking through the ER lumen, but compared with current 
knowledge on quality control of the glycoproteins, little is known on their quality 
control process. It is of no doubt non-glycosylated proteins also subject to ERQC and 
ERAD, as suggested by studies on some non-glycosylated substrates in both yeast and 
mammalian cells (Hirao et al., 2006; Hosokawa et al., 2008; Nakatsukasa et al., 2001; 
Olivari et al., 2005). Although all of these non-glycosylated proteins are degraded 
independent of Htm1p or its mammalian homolog EDEM, several other components 
are shared with glycoprotein substrates such as the Hrd1p-Hrd3p complex, suggesting 
the underlying mechanism is similar. Finding out how non-glycosylated protein 
quality control works would provide us more comprehensive understanding on the 




Materials and Methods 
 
2.1. S. cerevisiae strains and genetic methods 
 
2.1.1. List of strains used in this study (Table 2.1) 
 
2.1.2. Media for culturing S. cerevisiae 
 
W303a cells are cultured in yeast peptone dextrose (YPD) media (10 g/L yeast extract, 
20 g/L peptone, 2% dextrose/glucose) at 30℃, and other cells contain plasmids are 
cultured at 30℃ in synthetic complete (SC) media (7 g/L yeast nitrogen base, 2% 
dextrose/glucose, various aa mix) lacking appropriate component for plasmid 
selection. Sporulation of diploid strains are carried out in sporulation (SPO) media (3 
g/L KOAc, 0.2 g/L raffinose) at room temperature (RT). All solid media plates contain 
2% bacto-agar. Temperature sensitive mutant cells are grown at permissive 
temperature of 25℃  and shifted to restrictive temperature of 37℃  for gene 
inactivation. 
 
2.1.3. Mating and sporulation of S. cerevisiae 
 
Grow up two strains of opposite mating type 1 day beforehand. In the morning, use a 
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Table 2.1. List of yeast strains used in this study. 
Strain   Genotype             Source 
W303a  MATa, leu2-3, 112, his3-11, trp1-1, ura3-1, can1-100, ade2-1   P. Walter 
WXY3  MATa, pWX2, W303 background        This study 
WXY9  MATa, htm1::KANMX, pWX2, W303 background     This study 
WXY56  MATa, pWX29, W303 background        This study 
WXY57  MATa, pWX30, W303 background        This study 
WXY58  MATa, pWX31, W303 background        This study 
WXY81  MATa, pWX41, W303 background        This study 
WXY63  MATa, pWX22, W303 background        This study 
WXY103  MATa, pWX51, W303 background        This study 
WXY104  MATa, htm1::KANMX, pWX51, W303 background     This study 
WXY145  MATa, pWX75, W303 background        This study 
WXY148  MATa, hrd1::KANMX, pWX75, W303 background     This study 
WXY183  MATa, hrd1::KANMX, pWX2, W303 background     This study 
WXY185  MATa, cue1::TRP1, pep4::HIS3, prc1::KANMX,     This study 
pWX87, W303 background 
WXY192  MATa, prc1::KANMX, pWX94, W303 background     This study 
WXY193  MATa, prc1::KANMX, pWX96, W303 background     This study 
WXY196  MATa, pWX99, W303 background        This study 
WXY197  MATa, pWX100, W303 background        This study 
WXY198  MATa, pWX101, W303 background        This study 
WXY199  MATa, pWX102, W303 background        This study 
WXY200  MATa, pWX103, W303 background        This study 
WXY201  MATa, hrd1::KANMX, pWX99, W303 background     This study 
WXY202  MATa, hrd1::KANMX, pWX100, W303 background    This study 
WXY203  MATa, hrd1::KANMX, pWX101, W303 background    This study 
WXY204  MATa, hrd1::KANMX, pWX102, W303 background    This study 
WXY205  MATa, hrd1::KANMX, pWX103, W303 background    This study 
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Table 2.1. List of yeast strains used in this study (continued). 
Strain   Genotype             Source 
WXY220  MATa, pWX113, W303 background        This study 
WXY221  MATa, pWX114, W303 background        This study 
WXY222  MATa, pWX115, W303 background        This study 
WXY223  MATa, pWX116, W303 background        This study 
WXY206  MATa, cue1::TRP1, pep4::HIS3, prc1::KANMX,      This study 
pDN437, W303 background 
WXY207  MATa, cue1::TRP1, pep4::HIS3, prc1::KANMX,     This study 
pDN436, W303 background 
WXY208  MATa, cue1::TRP1, pep4::HIS3, prc1::KANMX,     This study 
pES132, W303 background 
WXY224  MATa, pWX107, W303 background        This study 
WXY225  MATa, pWX108, W303 background        This study 
WXY226  MATa, pWX109, W303 background        This study 
WXY227  MATa, pWX110, W303 background        This study 
WXY228  MATa, hrd1::KANMX, pWX107, W303 background    This study 
WXY229  MATa, hrd1::KANMX, pWX108, W303 background    This study 
WXY230  MATa, hrd1::KANMX, pWX109, W303 background    This study 
WXY231  MATa, hrd1::KANMX, pWX110, W303 background    This study 
WXY232  MATa, pWX121, W303 background        This study 
WXY233  MATa, pWX138, W303 background        This study 
WXY236  MATa, hrd1::KANMX, pWX121, W303 background    This study 
WXY237  MATa, hrd1::KANMX, pWX138, W303 background    This study 
WXY260  MATa, htm1::KANMX, pWX75, W303 background     This study 
WXY263  MATa, cue1::TRP1, pep4::HIS3, prc1::KANMX,     This study 
pRS316, W303 background 
WXY264  MATa, cue1::TRP1, pep4::HIS3, prc1::KANMX,     This study 
pES57, W303 background 
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Table 2.1. List of yeast strains used in this study (continued). 
Strain   Genotype             Source 
WXY265  MATa, cue1::TRP1, pep4::HIS3, prc1::KANMX,     This study 
pWX75, W303 background 
WXY266  MATa, pWX141, W303 background        This study 
WXY267  MATa, pWX142, W303 background        This study 
WXY268  MATa, pWX143, W303 background        This study 
WXY269  MATa, pWX144, W303 background        This study 
WXY270  MATa, pWX145, W303 background        This study 
WXY271  MATa, pWX146, W303 background        This study 
WXY275  MATa, pWX147, W303 background        This study 
WXY276  MATa, pWX148, W303 background        This study 
WXY277  MATa, pWX149, W303 background        This study 
WXY278  MATa, pWX150, W303 background        This study 
WXY279  MATa, pWX151, W303 background        This study 
WXY280  MATa, pWX152, W303 background        This study 
WXY281  MATa, htm1::KANMX, pWX147, W303 background    This study 
WXY282  MATa, htm1::KANMX, pWX148, W303 background    This study 
WXY283  MATa, htm1::KANMX, pWX149, W303 background    This study 
WXY284  MATa, htm1::KANMX, pWX150, W303 background    This study 
WXY285  MATa, htm1::KANMX, pWX151, W303 background    This study 
WXY286  MATa, htm1::KANMX, pWX152, W303 background    This study 
WXY287  MATa, hrd1::KANMX, pWX147, W303 background    This study 
WXY288  MATa, hrd1::KANMX, pWX148, W303 background    This study 
WXY289  MATa, hrd1::KANMX, pWX149, W303 background    This study 
WXY290  MATa, hrd1::KANMX, pWX150, W303 background    This study 
WXY291  MATa, hrd1::KANMX, pWX151, W303 background    This study 
WXY292  MATa, hrd1::KANMX, pWX152, W303 background    This study 
WXY294  MATa, prc1::KANMX, pWX140, W303 background    This study 
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Table 2.1. List of yeast strains used in this study (continued). 
Strain   Genotype             Source 
WXY295  MATa, prc1::KANMX, pWX114, W303 background    This study 
WXY296  MATa, prc1::KANMX, pWX116, W303 background    This study 
WXY299  MATa, pWX157, W303 background        This study 
WXY300  MATa, pWX158, W303 background        This study 
WXY301  MATa, pWX159, W303 background        This study 
WXY302  MATa, pWX160, W303 background        This study 
WXY303  MATa, pWX166, W303 background        This study 
WXY304  MATa, pWX167, W303 background        This study 
WXY305  MATa, pWX168, W303 background        This study 
WXY306  MATa, pWX169, W303 background        This study 
WXY307  MATa, htm1::KANMX, pWX166, W303 background    This study 
WXY308  MATa, htm1::KANMX, pWX167, W303 background    This study 
WXY309  MATa, htm1::KANMX, pWX168, W303 background    This study 
WXY310  MATa, htm1::KANMX, pWX169, W303 background    This study 
WXY311  MATa, hrd1::KANMX, pWX166, W303 background    This study 
WXY312  MATa, hrd1::KANMX, pWX167, W303 background    This study 
WXY313  MATa, hrd1::KANMX, pWX168, W303 background    This study 
WXY314  MATa, hrd1::KANMX, pWX169, W303 background    This study 
WXY315  MATa, pWX163, W303 background        This study 
WXY316  MATa, pWX164, W303 background        This study 
WXY317  MATa, htm1::KANMX, pWX163, W303 background    This study 
WXY318  MATa, htm1::KANMX, pWX164, W303 background    This study 
WXY319  MATa, hrd1::KANMX, pWX163, W303 background    This study 
WXY320  MATa, hrd1::KANMX, pWX164, W303 background    This study 
WXY321  MATa, pWX165, W303 background        This study 
WXY322  MATa, htm1::KANMX, pWX165, W303 background    This study 
WXY323  MATa, hrd1::KANMX, pWX165, W303 background    This study 
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Table 2.1. List of yeast strains used in this study (continued). 
Strain   Genotype             Source 
KKY62  MATa, pKK129, W303 background        This study 
KKY63  MATa, htm1::KANMX, pKK129, W303 background     This study 
KKY88  MATa, yos9::KANMX, pKK129, W303 background     This study 
KKY126  MATa, pKK156, W303 background        This study 
KKY127  MATa, pKK157, W303 background        This study 
KKY128  MATa, pKK158, W303 background        This study 
KKY129  MATa, pKK159, W303 background        This study 
KKY130  MATa, pKK160, W303 background        This study 
KKY131  MATa, pKK161, W303 background        This study 
KKY132  MATa, pKK162, W303 background        This study 
KKY133  MATa, pKK163, W303 background        This study 
KKY134  MATa, pKK164, W303 background        This study 
KKY143  MATa, htm1::KANMX, pKK163, W303 background     This study 
KKY191  MATa, pKK214, W303 background        This study 
KKY192  MATa, htm1::KANMX, pKK214, W303 background     This study 
KKY201  MATa, pKK216, W303 background        This study 
KKY202  MATa, pJB113, W303 background        This study 
KKY203  MATa, pJB114, W303 background        This study 
KKY204  MATa, pKK218, W303 background        This study 
KKY206  MATa, pKK210, W303 background        This study 
KKY273  MATa, pKK228, W303 background        This study 
KKY354  MATa, pKK232, W303 background        This study 
KKY355  MATa, htm1::KANMX, pKK232, W303 background     This study 
KKY357  MATa, hrd1::KANMX, pKK232, W303 background     This study 
KKY595  MATa, pKK249, W303 background        This study 
KKY596  MATa, htm1::KANMX, pKK249, W303 background     This study 
KKY597  MATa, hrd1::KANMX, pKK249, W303 background     This study 
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Table 2.1. List of yeast strains used in this study (continued). 
Strain   Genotype             Source 
KKY604  MATa, pKK252, W303 background        This study 
KKY605  MATa, htm1::KANMX, pKK252, W303 background     This study 
KKY606  MATa, hrd1::KANMX, pKK252, W303 background     This study 
KKY613  MATa, hrd1::KANMX, pJB114, W303 background     This study 
KKY622  MATa, pKK261, W303 background        This study 
KKY623  MATa, htm1::KANMX, pKK261, W303 background     This study 
KKY624  MATa, hrd1::KANMX, pKK261, W303 background     This study 
KKY631  MATa, htm1::KANMX, pWX99, W303 background     This study 
KKY632  MATa, htm1::KANMX, pWX100, W303 background    This study 
KKY633  MATa, htm1::KANMX, pJB114, W303 background     This study 
KKY634  MATa, htm1::KANMX, pWX101, W303 background    This study 
KKY635  MATa, htm1::KANMX, pWX102, W303 background    This study 
KKY636  MATa, htm1::KANMX, pWX103, W303 background    This study 
KKY655  MATa, pep4::HIS3, pKK261, W303 background     This study 
KKY666  MATa, yos9::KANMX, pKK129, pKK278, W303 background   This study 
KKY667  MATa, yos9::KANMX, pKK261, pKK278, W303 background   This study 
KKY678  MATa, yos9::KANMX, pKK261, W303 background     This study 
KKY697  MATa, yos9::KANMX, pKK252, W303 background     This study 
KKY699  MATa, der1::KANMX, pKK252, W303 background     This study 
KKY704  MATa, der1::KANMX, pKK261, W303 background     This study 
KKY720  MATa, yos9::KANMX, pKK129, pKK284, W303 background   This study 
KKY721  MATa, yos9::KANMX, pKK261, pKK284, W303 background   This study 
KKY739  MATa, pKK129, pKK286, W303 background      This study 
KKY740  MATa, pKK261, pKK286, W303 background      This study 
KKY745  MATa, pKK129, pRS315, W303 background      This study 
KKY746  MATa, pKK261, pRS315, W303 background      This study 
KKY755  MATa, usa1::KANMX, pKK261, W303 background     This study 
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Table 2.1. List of yeast strains used in this study (continued). 
Strain   Genotype             Source 
KKY756  MATa, usa1::KANMX, pKK252, W303 background     This study 
KKY931  MATa, pRH244, W303 background        This study 
KKY932  MATa, hrd1::KANMX, pRH244, W303 background     This study 
KKY933  MATa, yos9::KANMX, pRH244, W303 background     This study 
KKY934  MATa, der1::KANMX, pRH244, W303 background     This study 
KKY976  MATa, cue1::KANMX, pRH244, W303 background     This study 
KKY977  MATa, htm1::KANMX, pRH244, W303 background     This study 
KKY978  MATa, usa1::KANMX, pRH244, W303 background     This study 
KKY993  MATa, cdc48-1, pKK261, W303 background      This study 
KKY992  MATa, cue1::KANMX, pKK261, W303 background     This study 
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toothpick to take some cells from the first strain, transfer onto an YPD plate. Take 
some cells from second strain, transfer onto YPD plate next to first strain. Mix the two 
cell clumps together and allow them to mate for 4-5 hours at 30℃. Take some cells 
from the mating reaction and make 4 streaks on one half of a new thin YPD plate. 
Bring the plate to microscope to pick zygotes. Pick 3 zygotes per cross and allow 
colonies to grow at 30℃ for 3 days. Inoculate some cells into 3 mL of SPO media and 
incubate at 25℃ on roller for 3 days. Then take out 200-300 μL of the culture in SPO 
media, spin down cells for 15 seconds at 14,000 rpm and remove supernatant 
completely. Add 20 μL of 1 mg/mL zymolyase-20T solution (10 mM Tris-HCl, 1 M 
sorbitol, pH 7.4). Resuspend pellet and incubate for 10-12 minutes at RT. Add 180 μL 
of 1 M sorbitol solution (10 mM Tris-HCl, 1 M sorbitol, pH 7.4) to dilute out 
zymolyase. Mix gently and spread 30 μL of mixture onto another thin YPD plate. 
Bring the plate to microscope to pick tetrads. 
 
2.1.4. Transformation of S. cerevisiae 
 
2.1.4.1. Low efficiency plasmid transformation 
 
Add 100 μL PLATE mix (40% PEG-3350, 0.1 M LiOAc, 10 mM Tris-HCl, 1 mM 
EDTA, pH 7.4), 200-300 ng plasmid DNA, 3 μL ssDNA (sonicated salmon sperm 
DNA, boiled for 10 minutes and cooled on ice for 3 minutes) and cells from a fresh 
culture in a tube. Vortex to mix and incubate at RT for 3-6 hours. Spin cells down at 
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14,000 rpm for 15 seconds and remove 80 μL supernatant. Resuspend the cells in the 
rest of the supernatant and plate on selective media plate. Incubate the plate at 30℃ 
for 2 days and pick single colony transformant. 
 
2.1.4.2. Preparation of yeast competent cells 
 
Grow cells at 30℃ to 0.4-0.8 OD600 in 50 mL YPD liquid media. Pellet cells at 2,000 
rpm for 5 minutes at RT. Wash cells with 20 mL LiOAc mix (0.1 M LiOAc, 10 mM 
Tris-HCl, 1 mM EDTA, pH 7.4) once. Resuspend cells in 1mL LiOAc mix and the 
cells are ready for high efficiency DNA fragment transformation. 
 
2.1.4.3. High efficiency DNA fragment transformation 
 
Add 700 μL PLATE mix, 2-3 μg purified DNA fragment, 10 μL ssDNA and 150 μL 
freshly prepared yeast competent cells in a tube. Vortex to mix and incubate at 30℃ 
for 30-60 minutes. Add DMSO to 12% final concentration, mix well and heat shock 
the cells at 42℃ for 22 minutes. Spin cells down at 14,000 rpm for 30 seconds and 
remove supernatant completely. Resuspend the cells in 200 μL YPD media (for 
KANMX selection) or SC selection media (for other selection markers) and recover at 
30℃ for 1 hour. Plate on respective selection media, incubate at 30℃ for 2 days and 




2.2. Molecular biology methods 
 
2.2.1. List of plasmids used in this study (Table 2.2) 
 
All ERAD substrate constructs were confirmed by nucleotide sequencing over the 
entire length of their open reading frames. Unless otherwise noted in the text, ERAD 
substrates contained HA epitope tags at their C-terminus. Amino acid positions are 
designated using translation initiator methionines as position 1. 
 
2.2.2. List of oligonucleotide primers used in this study (Table 2.3) 
 
2.2.3. Plasmid construction 
 
The following plasmids were generated using site-directed mutagenesis of ERAD 
substrate clones (Sawano and Miyawaki, 2000). Substrate variant names are indicated 
in parentheses. Primer sequences are listed in section 2.2.2. All substrate genes are 
controlled by their endogenous promoters and encode the HA-epitope tag at their 
C-termini. 
pWX2 (PrA*-∆155-405). The WXN2 primer was used to delete a segment encoding 
Lys105 to Ile405 from pKK129.  
pWX22 (CPY*-abcB). A 0.5 kb fragment was amplified from pES129 using WXN24 
and kinased WXN23 primers, digested with XbaI and purified. In parallel, a fragment 
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Table 2.2. List of plasmids used in this study. 
Plasmid Protein      Primers used  Vector   Source 
pDN436  CPY*        -    pRS315     Ng et al., 2000 
pDN437  CPY         -    pRS315     Ng et al., 2000 
pES57  CPYΔ1        -    pRS316   Spear et al., 2005 
pES129  CPY*-aBCD       -    pRS315   Spear et al., 2005 
pES132  CPY*-ABCd       -    pRS315   Spear et al., 2005 
pES147  CPY*-abcD       -    pRS316   Spear et al., 2005 
pRH244  Hmg2           -        R. Hampton 
pKK218  CPY*-abcD-Δ298-388  JBN162   pRS316   This study 
pKK228  CPY*-abcD-Δ389-476  KKN195   pRS316   This study 
pKK210  CPY*-abcD-Δ482-532    N572, N573  pRS316   This study 
pWX2  PrA*-Δ155-405   WXN2   pRS316   This study 
pWX22  CPY*-abcB    WXN101, WXN22  pRS316   This study 
         WXN23, WXN24 
pWX29  PrA*-GIΔ2    WXN29   pRS316   This study 
pWX30  PrA*-GIΔ3    WXN30   pRS316   This study 
pWX31  PrA*-GIΔ4    WXN31   pRS316   This study 
pWX41  PrA*-GIΔ1    WXN41   pRS316   This study 
pWX51  PrA*-GIΔ4CHO   WXN31   pRS316   This study 
pWX75  CPYΔ2     WXN75   pRS316   This study 
pWX87  CPY*        -    pRS316   This study 
pWX92  CPY-ABCD    WXN92, WXN93  pRS316   This study 
pWX93  CPY-abcd    WXN92, WXN93  pRS316   This study 
pWX94  CPY-ABCD-C328P   WXN94   pRS316   This study 
pWX95  CPY-abcd-C328P   WXN94   pRS316   This study 
pWX96  CPY-ABCD-C351P   WXN96   pRS316   This study 




Table 2.2. List of plasmids used in this study (continued). 
Plasmid Protein      Primers used  Vector   Source 
pWX99  CPY-abcD-Δ25-117   WXN99, WXN100  pRS316   This study 
         WXN101, WXN102 
pWX100  CPY-abcD-Δ116-206  WXN99, WXN100  pRS316   This study 
         WXN101, WXN102 
pWX101  CPY-abcD-Δ298-388  WXN99, WXN100  pRS316   This study 
         WXN101, WXN102 
pWX102  CPY-abcD-Δ389-476  WXN99, WXN100  pRS316   This study 
         WXN101, WXN102 
pWX103  CPY-abcD-Δ482-532  WXN99, WXN100  pRS316   This study 
         WXN101, WXN102 
pWX107  CPY-abcD-C328P      -    pRS316   This study 
pWX108  CPY-ABCd-C328P      -    pRS316   This study 
pWX109  CPY-abcD-C351P      -    pRS316   This study 
pWX110  CPY-ABCd-C351P      -    pRS316   This study 
pWX113  CPY-ABCD-S194K  WXN113F, WXN113R pRS316   This study 
        WXN101, WXN102 
pWX114  CPY-ABCD-G227R  WXN114F, WXN114R pRS316   This study 
        WXN101, WXN102 
pWX116  CPY-ABCD-I451R  WXN116F, WXN116R pRS316   This study 
        WXN101, WXN102 
pWX120  CPY-abcd-I451R  WXN116F, WXN116R pRS316   This study 
        WXN101, WXN102 
pWX121  CPY-ABCd-S194K      -    pRS316   This study 
pWX130  PrA-ab        -    pRS316   This study 
pWX138  CPY-abcD-S194K   WXN138   pRS316   This study 
pWX140  CPY-abcD       -    pRS316   This study 
pWX141  CPY-ABCD-Δ112-123  WXN141   pRS316   This study 
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Table 2.2. List of plasmids used in this study (continued). 
Plasmid Protein      Primers used  Vector   Source 
pWX142  CPY-ABCD-Δ127-138  WXN142   pRS316   This study 
pWX143  CPY-ABCD-Δ185-196  WXN143   pRS316   This study 
pWX144  CPY-ABCD-Δ201-212  WXN144   pRS316   This study 
pWX145  CPY-ABCD-Δ267-278  WXN145   pRS316   This study 
pWX146  CPY-ABCD-Δ282-293  WXN146   pRS316   This study 
pWX147  CPY-Abcd-Δ112-123  WXN141   pRS316   This study 
pWX148  CPY-Abcd-Δ127-138  WXN142   pRS316   This study 
pWX149  CPY-aBcd-Δ185-196  WXN143   pRS316   This study 
pWX150  CPY-aBcd-Δ201-212  WXN144   pRS316   This study 
pWX151  CPY-abCd-Δ267-278  WXN145   pRS316   This study 
pWX152  CPY-abCd-Δ282-293  WXN146   pRS316   This study 
pWX163  CPY*-abCd-Δ267-278  WXN163   pRS316   This study 
pWX164  CPY*-abCd-Δ282-293  WXN163   pRS316   This study 
pWX165  CPY*-abcB-Δ482-532  WXN165   pRS316   This study 
pWX157  PrA-AB-N88D    WXN157   pRS316   This study 
pWX158  PrA-AB-G199K   WXN158   pRS316   This study 
pWX159  PrA-AB-G233K   WXN159   pRS316   This study 
pWX160  PrA-AB-I365R    WXN160   pRS316   This study 
pWX161  PrA-ab-G199K    WXN158   pRS316   This study 
pWX162  PrA-ab-I365R    WXN160   pRS316   This study 
pWX166  PrA-Ab-G199K      -    pRS315   This study 
pWX167  PrA-aB-G199K      -    pRS315   This study 
pWX168  PrA-Ab-I365R       -    pRS315   This study 
pWX169  PrA-aB-I365R       -    pRS315   This study 
pKK129  PrA*-Ab        -    pRS316   This study 
pKK156  PrA*-Ab-Δ37-71   KKN129   pRS316   This study 
pKK157  PrA*-Ab-Δ72-106   KKN130   pRS316   This study 
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Table 2.2. List of plasmids used in this study (continued). 
Plasmid Protein      Primers used  Vector   Source 
pKK158  PrA*-Ab-Δ110-146   KKN131   pRS316   This study 
pKK159  PrA*-Ab-Δ147-183   KKN132   pRS316   This study 
pKK160  PrA*-Ab-Δ184-220   KKN133   pRS316   This study 
pKK161  PrA*-Ab-Δ221-257   KKN134   pRS316   This study 
pKK162  PrA*-Ab-Δ258-294   KKN135   pRS316   This study 
pKK163  PrA*-Ab-Δ295-331   KKN136   pRS316   This study 
pKK164  PrA*-Ab-Δ332-368   KKN137   pRS316   This study 
pKK214  PrA*-AbΔ147-183,   KKN136   pRS316   This study 
295-331-HA 
pKK216  CPY*-abcD-Δ25-117  JBN159   pRS316   This study 
pKK232  PrA*-GI     KKN228   pRS316   This study 
pKK247  PrA-AB    KKN274, KKN275  pRS316   This study 
pKK249  ngPrA*Δ295-331-HA        -    pRS316   This study 
pKK252  PrA-CTD     KKN279   pRS316   This study 
pKK261  ngPrAΔ295-331-HA          -    pRS316   This study 
pKK278  Yos9        KKN303   pRS313   This study 
pKK284  Yos9R200A       KKN306   pRS313   This study 
pKK286  CPY*     KKN307   pRS315   This study 
pJB113  CPY*-abcD-Δ116-206  JBN160   pRS316   This study 
pJB114  CPY-abcD-Δ207-297  JBN161   pRS316   This study 
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Table 2.3. List of oligonucleotide primers used in this study. 
Primer  Mutation   Sequence (5’→3’) 
WXN2  PrA*-Δ155-405   5’-AATTTGCCATTCAATATGGTACTT 
ACCCATATGATGTTCCAGATTACG-3’ 
WXN22  CPY*-abcB    ATCGTAAACGTTTCTGCCGGTACG 
WXN23  CPY*-abcB    ATCAAAACGAAGAAAGACTGGGAC 
WXN24  CPY*-abcB    5’-CCCCCTCTAGATTAAGCGTAATCTGGAACATC 
ATATGGGTAGAAATCTTGGCCCTTGTTGACGTA-3’ 
WXN29  PrA*-GIΔ2    5’-ACCTCAAAACTTCAAGGTTATTTTG 
GAGGCTACCAGCGATTTGTTGGACG-3’ 
WXN30  PrA*-GIΔ3    5’-GACCATTCCAAAACAAGACTTCGCT 
AGCCATGGTGCCGCCATCGATACTG-3’ 
WXN31  PrA*-GIΔ4    5’-AGGCGACGAGTACGCCGAATTGGA 
GTACCCATATGATGTTCCAGATTACG-3’ 
WXN41  PrA*-GIΔ1    5’-GGTCAGCGCCAACCAAGTTGCTGCA 
GATACTGGTTCTTCAAACCTTTGGG-3’ 
WXN75  CPYΔ2    5’-CTGTCCACTACACTCGCTAAGGCC 
ATCAGGAAGGATTGTGAAGGTGGC-3’ 
WXN92  CPY-ABCD   5’-CACCGCGGTGGCGGCCGCTCTAGAGCTGAGGCTACCA 
   CPY-abcd       GCGAGCCGGGCTTATTAGGTCTCTTATGGTAGTTTTTA-3’ 
WNX93  CPY-ABCD   5’-GCCTTAAGTATGGTTAACGAATGGA 
CPY-abcd       TTCACGGTGGTTTCTCCTTATACCCA-3’ 
WXN94  CPY-ABCD-C328P  5’-GCTATGGAAGACTCTTTGGAACGTC 
CPY-abcd-C328P      CTTTGGGCTTGATCGAGTCGTGCTAT-3’ 
WXN96  CPY-ABCD-C351P  5’-TCCTGTGTTCCAGCTACCATTTATCC 
CPY-abcd-C351P      TAATAACGCCCAATTGGCTCCTTAC-3’ 





Table 2.3. List of oligonucleotide primers used in this study (continued). 
Primer  Mutation   Sequence (5’→3’) 
CPY-abcD-Δ389-476 
CPY-abcD-Δ482-532 



























Table 2.3. List of oligonucleotide primers used in this study (continued). 
Primer  Mutation   Sequence (5’→3’) 
WXN113F  CPY-ABCD-S194K  AAGTGGAACAGCAATGCCACCGTGATC 
WXN113R  CPY-ABCD-S194K  GTAAGGGTTCCCGATGGGTTTCAA 
WXN114F  CPY-ABCD-G227R  AGGAAGGATGTCTATAACTTCTTGGAG 
WXN114R  CPY-ABCD-G227R  AGCGGCGACAGTGTTGGAAACACC 
WXN116F  CPY-ABCD-I451R  AGGTGTAACTGGTTGGGTAATAAGGCG 
   CPY-abcd-I451R 
WXN116R  CPY-ABCD-I451R  GAAATCTTTATCGCCTGCATATAC 
   CPY-abcd-I451R 
WXN138  CPY-abcD-S194K  5’-GGGAACCCTTACAAGTGGAACAGCC 
AGGCCACCGTGATCTTCCTTGACCAG-3’ 
WXN141  CPY-ABCD-Δ112-123  5’-GAAAACTATCAGCTTCGTGTCAAC 
CPY-Abcd-Δ112-123     AATGTCACACAGTACACGGGTTAC-3’ 
WXN142  CPY-ABCD-Δ127-138  5’-CTGGGCATTGACCCAAATGTCAC 
CPY-Abcd-Δ127-138     AAAGCATTTCTTCTTTTGGACTTTT-3’ 
WXN143  CPY-ABCD-Δ185-196  5’-TTAGGACCCTCATCCATTGGACCT 
CPY-aBcd-Δ185-196     AGCAATGCCACCGTGATCTTCCTT-3’ 
WXN144  CPY-ABCD-Δ201-212  5’-TACTCTTGGAACAGCAATGCCACC 
CPY-aBcd-Δ201-212     TCGTATTCCGGGTCCTCAGGTGTT-3’ 
WXN145  CPY-ABCD-Δ267-278  5’-GCCGGCCATTACATCCCTGTTTTT 
CPY-abCd-Δ267-278     AACTTAACCTCCGTCTTGATCGGA-3’ 
WXN146  CPY-ABCD-Δ282-293  5’-AAGGACAGAAACTTCAACTTAACC 
CPY-abCd-Δ282-293     ACTCAGTATAACTATTACGAACCA-3’ 
WXN157  PrA-AB-N88D   5’-GATGTTCCATTGACAAATTACTTGG 
ACGCACAATATTACACTGACATTACT-3’ 
WXN158  PrA-AB-G199K   5’-TTTGGCAAGTTCGATGGTATTTTGA 




Table 2.3. List of oligonucleotide primers used in this study (continued). 
Primer  Mutation   Sequence (5’→3’) 
WXN159  PrA-AB-G233K   5’-GAAAAGAGATTTGCCTTTTATTTGAA 
GGACACTTCAAAGGATACTGAAAAT-3’ 
WXN160  PrA-AB-I365R   5’-GTTTCAGGCTCCTGTATCTCTGCACG 
PrA-ab-I365R      TACACCAATGGATTTCCCAGAACCT-3’ 
WXN163  CPY*-abCd-Δ267-278  5’-AAGGGCCAAGATTTCCACATCGCTA 
CPY*-abCd-Δ282-293     GAGAATCCTACGCCGGCCATTACATC-3’ 
WXN165  CPY*-abcB-Δ482-534  5’-AACCCTTACTCTTGGAACAGCAATG 
CCACCTACCCATATGATGTTCCAGAT-3’ 
KKN129  PrA*-Ab-Δ37-71   ATAAACACGAGTTGTCCGATGATACTGGTTCTTCAAACCT 
KKN130  PrA*-Ab-Δ72-106  AAAACTTCAAGGTTATTTTGAATGGTACTGAATTTGCCAT 
KKN131  PrA*-Ab-Δ110-146  GCTACAAAGCTAATGGTACTGAGCCGGGCTTAACATTTGC 
KKN132  PrA*-Ab-Δ147-183  ACTTCGCTGAGGCTACCAGCGATTTGTTGGACGAAAAGAG 
KKN133  PrA*-Ab-Δ184-220  TTTACAACGCCATTCAACAAGATATCACTTGGTTACCTGT 
KKN134  PrA*-Ab-Δ221-257  ACGAGTCTAAGTTCAAGGGCACTGGTACTTCTTTGATTAC 
KKN135  PrA*-Ab-Δ258-294  GCCATGGTGCCGCCATCGATGACAATCTACCTGATCTAAT 
KKN136  PrA*-Ab-Δ295-331  CTCTAGACTGTAACACCAGAGATTTCCCAGAACCTGTTGG 
KKN137  PrA*-Ab-Δ332-368  TCTCTGCAATTACACCAATGTACCCATATGATGTTCCAGA 
KKN195  CPY*-abcD-Δ389-476  CGTTACAAGATATCGACGACGTACGTAACTGGACTGCTTC 
KKN228  PrA*-GI    5’-GAAGCTTCATCAAGCTACAAAGCTC 
AGGGTACTGAATTTGCCATTCAATAT-3’ 
KKN274  PrA-AB    GCCTATCGATTCGCAATCACAAATTGATCCTAGTAAGAAG 
KKN275  PrA-AB    GGAGCCTGAAACTTCAAGCGTGTAATCGTA 
KKN279  PrA-CTD    5’-AGTTGCTGCAAAAGTCCACAAGGCT 
AGCCATGGTGCCGCCATCGATACTG-3’ 





Table 2.3. List of oligonucleotide primers used in this study (continued). 
Primer  Mutation   Sequence (5’→3’) 
KKN306  Yos9R200A   5’-TTGCGATGTGACGGGGGCTGAAGC 
AATGGTTGAAATACAATATGTCTG-3’ 
KKN307  CPY*    5’-ATGGATCCACGGTGGTTTCTCCTTA 
TAGTCTAGATAATCTCTGCTTTTGT-3’ 
JBN159  CPY*-abcD-Δ25-117  CTAAGGCCATCTCATTGCAAATCCTGGGCATTGACCCACAG 
JBN160  CPY*-abcD-Δ116-206  GTGTCAACAAGATTAAGGACCCTGTCAACGTTGGGTTCTC 
JBN161  CPY-abcD-Δ207-297  CCGTGATCTTCCTTGACCAGTATTACGAACCAATGGCCTG 
JBN162  CPY*-abcD-Δ298-388  GACCCATTGACTCAGTATAACTACTTAAACCAGGACTACGTC 
N572   CPY*-abcD-Δ482-532  AGTCCAGTTACGTACTTT 




was amplified from pES147 using WXN101 and kinased WXN22 primers, digested 
with NotI and the 1.8 kb fragment purified. Then these two fragments were inserted 
into pRS316 digested with NotI and XbaI to create pWX22. 
pWX29 (PrA*-GI∆2). Using the WXN29 oligonucleotide, a segment encoding Asp72 
through Ala142 was deleted from pKK232. 
pWX30 (PrA*-GI∆3). Using the WXN30 oligonucleotide, a segment encoding 
Glu143 through Glu213 was deleted from pKK232. 
pWX31 (PrA*-GI∆4). Using the WXN31 oligonucleotide, a segment encoding 
Ser214 through Ile284 was deleted from pKK232. 
pWX41 (PrA*-GI∆1). Using the WXN41 oligonucleotide, a segment encoding Lys23 
through Leu71 was deleted from pKK232. 
pWX51 (PrA*-GI∆4CHO). Using the WXN31 oligonucleotide, a segment encoding 
Ser214 through Ile284 was deleted from pKK214. 
pWX75 (CPY∆2). The WXN75 primer was used to delete a segment encoding Ile21 
to Asp368 from pKK129.  
pWX87 (CPY*). A 2.8 Kb NotI to XhoI fragment from pDN436 inserted into pRS316. 
pWX92 (CPY-ABCD). This plasmid expresses wild-type CPY containing a 
C-terminal HA tag. Using primers WXN92 and WXN93, two BamHI sites on 
pDN437 were destroyed while maintaining the native peptide sequence. This was 
done to facilitate the construction of more complex variants. The gene was sub-cloned 
into pRS316 vector digested with NotI and XhoI to generate pWX92.  
pWX93 (CPY-abcd) was constructed similarly to pWX92 but the non-glycosylated 
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CPY ORF was used as a template. 
pWX94 (CPY-ABCD-C328P) and pWX95 (CPY-abcd-C328P) were generated by site 
directed mutagenesis with pWX92 and pWX93 as templates, respectively, using the 
WXN94 primer to convert Cys328 to Pro351. 
pWX96 (CPY-ABCD-C351P) and pWX97 (CPY-ABCD-S194K) were generated by 
site directed mutagenesis with pWX92 and pWX93 as templates, respectively, using 
the WXN96 primer to convert Cys351 to Pro351. 
pWX99 (CPY-abcD-∆25-117). A 1.6 kb fragment was amplified from pKK216 using 
primers WXN101 and kinased WXN100, digested with NotI and purified. In parallel, 
1.3 kb fragment was amplified from pKK216 using primers WXN102 and kinased 
WXN99, digested with XhoI and purified. Then these two fragments were inserted 
into pRS316 digested with NotI and XhoI to generate pWX99. 
pWX100 (CPY-abcD-∆116-206), pWX101 (CPY-abcD-∆298-388), pWX102 
(CPY-abcD-∆389-476), pWX103 (CPY-abcD-∆482-532). These plasmids were 
constructed as described for pWX99 except that pJB113, pKK218, pKK228, and 
pKK210 were used as templates, respectively. 
pWX107 (CPY-abcD-C328P). A 2.0 kb NotI/BglII fragment from pWX95 and a 0.8 
kb BglII/XhoI fragment from pWX94 were inserted into pRS316 digested with NotI 
and XhoI.  
pWX108 (CPY-ABCd-C328P). A 2.0 kb NotI/BglII fragment from pWX94 and a 0.8 




pWX109 (CPY-abcD-C351P). A 2.0 kb NotI/BglII fragment from pWX97 and a 0.8 
kb BglII/XhoI fragment from pWX96 were ligated into pRS316 digested with NotI 
and XhoI. 
pWX110 (CPY-ABCd-C351P). A 2.0 kb NotI/BglII fragment from pWX96 and a 0.8 
kb BglII/XhoI fragment from pWX97 were ligated into pRS316 digested with NotI 
and XhoI. 
pWX113 (CPY-ABCD-S194K). A 1.4 kb fragment was amplified from pKK92 using 
WXN101 and kinased WXN113R primers, digested with NotI and purified. In parallel, 
a 1.5 kb fragment was amplified from pKK92 using primers WXN102 and kinased 
WXN113F, digested with XhoI and purified. The fragments were inserted into 
pRS316 digested with NotI and XhoI to create pWX113.  
pWX114 (CPY-ABCD-G227R), pWX116 (CPY-ABCD-I451R) and pWX120 
(CPY-abcd-I451R) were constructed as described for pWX113 using the primer sets 
[WXN114F/WXN114R; WXN101/WXN102], [WXN116F/WXN116R; 
WXN101/WXN102], and [WXN116F/WXN116R; WXN101/WXN102], respectively. 
pWX140 (CPY-abcD). A 2.0 kb NotI/BglII fragment from pWX92 and a 0.8 kb 
BglII/XhoI fragment from pWX93 were ligated into pRS316 digested with NotI and 
XhoI. 
pWX121 (CPY-ABCd-S194K). A 2.0 kb NotI/BglII fragment from pWX113 and a 0.8 
kb BglII/XhoI fragment from pWX93 were ligated into pRS316 digested with NotI 
and XhoI. 
pWX138 (CPY-abcD-S194K). Site-directed mutagenesis on pWX140 using the 
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WXN138 primer was performed to convert Ser194 to Lys194. 
pWX141 (CPY-ABCD-∆112-123). The WXN141 primer was used to delete a 
segment encoding Lys112 to Pro123 from pWX92.  
pWX142 (CPY-ABCD-∆127-138). The WXN142 primer was used to delete a 
segment encoding Gln127 to Asp138 from pWX92. 
pWX143 (CPY-ABCD-∆185-196). The WXN143 primer was used to delete a 
segment encoding Asp185 to Asn196 from pWX92. 
pWX144 (CPY-ABCD-∆201-212). The WXN144 primer was used to delete a 
segment encoding Val201 to Phe212 from pWX92. 
pWX145 (CPY-ABCD-∆267-278). The WXN145 primer was used to delete a 
segment encoding Ala267 to Phe278 from pWX92. 
pWX146 (CPY-ABCD-∆282-293). The WXN146 primer was used to delete a 
segment encoding Ser282 to Leu293 from pWX92. 
pWX147 (CPY-Abcd-∆112-123). The WXN141 primer was used to delete a segment 
encoding Lys112 to Pro123 from pWX93 and simultaneously restoring the A glycan 
site. 
pWX148 (CPY-Abcd-∆127-138). The WXN142 primer was used to delete a segment 
encoding Gln127 to Asp138 from pWX93 and simultaneously restoring the A glycan 
site. 
pWX149 (CPY-aBcd-∆185-196). The WXN143 primer was used to delete a segment 




pWX150 (CPY-aBcd-∆201-212). The WXN144 primer was used to delete a segment 
encoding Val201 to Phe212 from pWX93 and simultaneously restoring the B glycan 
site. 
pWX151 (CPY-abCd-∆267-278). The WXN145 primer was used to delete a segment 
encoding Ala267 to Phe278 from pWX93 and simultaneously restoring the C glycan 
site. 
pWX152 (CPY-abCd-∆282-293). The WXN146 primer was used to delete a segment 
encoding Ser282 to Leu293 from pWX93 and simultaneously restoring the C glycan 
site. 
pWX157 (PrA-AB-N88D) was generated by site directed mutagenesis using the 
WXN157 primer on the pKK247 template to convert Asn88 to Asp88. 
pWX158 (PrA-AB-G199K) and pWX161 (PrA-ab-G199K) were generated by site 
directed mutagenesis with pKK247 and pWX130 as templates, respectively, using the 
WXN158 primer to convert Gly199 to Lys199. 
pWX159 (PrA-AB-G233K) was generated by site directed mutagenesis using the 
WXN159 primer on the pKK247 template to convert Gly233 to Lys233. 
pWX160 (PrA-AB-I365R) and pWX162 (PrA-ab-G199K) were generated by site 
directed mutagenesis with pKK247 and pWX130 as templates, respectively, using the 
WXN160 primer to convert Ile365 to Arg365. 
pWX163 (CPY*-abCd-∆267-278). The CPY* point mutation G255R was introduced 
into pWX151 using the WXN163 primer. 
pWX164 (CPY*-abCd-∆282-293). The CPY* point mutation G255R was introduced 
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into pWX152 using the WXN163 primer. 
pWX165 (CPY*-abcB-∆482-532). A DNA segment encoding Val482 to Phe532 was 
deleted from pWX22 using the WXN165 primer to create pWX165. 
pWX166 (PrA-Ab-G199K). A 1.7 kb XhoI/NcoI fragment from pWX158 and a 0.9 kb 
NcoI/NotI fragment from pWX161 were inserted into pRS315 digested with NotI and 
XhoI. 
pWX167 (PrA-aB-G199K). A 1.7 kb XhoI/NcoI fragment from pWX161 and a 0.9 kb 
NcoI/NotI fragment from pWX158 were inserted into pRS315 digested with NotI and 
XhoI. 
pWX168 (PrA-Ab-I365R). A 1.7 kb XhoI/NcoI fragment from pWX160 and a 0.9 kb 
NcoI/NotI fragment from pWX162 were inserted into pRS315 digested with NotI and 
XhoI. 
pWX169 (PrA-aB-I365R). A 1.7 kb XhoI/NcoI fragment from pWX162 and a 0.9 kb 
NcoI/NotI fragment from pWX160 were inserted into pRS315 digested with NotI and 
XhoI. 
pKK156 (PrA*-Ab-∆37-71). Using the KKN129 oligonucleotide, a segment encoding 
Glu37 through His71 was deleted from pKK129. 
pKK157 (PrA*-Ab-∆72-106). Using the KKN130 oligonucleotide, a segment 
encoding Pro72 to Val106 was deleted from pKK129. 
pKK158 (PrA*-Ab-∆110-146). Using the KKN131 oligonucleotide, a segment 
encoding Thr110 to Thr146 was deleted from pKK129. 
pKK159 (PrA*-Ab-∆147-183). Using the KKN132 oligonucleotide, a segment 
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encoding Glu147 to Ser183 was deleted from pKK129. 
pKK160 (PrA*-Ab-∆184-220). Using the KKN133 oligonucleotide, a segment 
encoding Glu184 to Gln220 was deleted from pKK129. 
pKK161 (PrA*-Ab-∆221-257). Using the KKN134 oligonucleotide, a segment 
encoding Asp221 to Gly257 was deleted from pKK129. 
pKK162 (PrA*-Ab-∆258-294). Using the KKN135 oligonucleotide, a segment 
encoding Asp258 to Asp294 was deleted from pKK129. 
pKK163 (PrA*-Ab-∆295-331). Using the KKN136 oligonucleotide, a segment 
encoding Thr295 to Arg331 was deleted from pKK129. 
pKK164 (PrA*-Ab-∆332-368). Using the KKN137 oligonucleotide, a segment 
encoding Asp332 to Met368 was deleted from pKK129. 
pKK214 (PrA*-Ab-∆147-183/295-331). Using the KKN136 oligonucleotide, a 
segment encoding Thr295 through Arg331 was deleted from pKK159. 
pKK216 (CPY*-abcD-∆25-117). Using the JBN159 oligonucleotide, a segment 
encoding Arg25 to Lys117 was deleted from pES147. 
pKK218 (CPY*-abcD-∆298-388). Using the JBN162 oligonucleotide, a segment 
encoding Tyr298 to Asp388 was deleted from pES147. 
pKK228 (CPY*-abcD-∆389-476). Using the KKN195oligonucleotide, a segment 
encoding Tyr389 to Lys476 was deleted from pES147. 
pKK232 (PrA*-GI). Using the KKN228 oligonucleotide, N-linked glycosylation site 
was mutagenized on pKK214. 
pKK252 (PrA-CTD). Using the KKN279 oligonucleotide, a segment encoding Lys26 
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through Ile284 was deleted from pKK150. 
pJB113 (CPY*-abcD-∆116-206). Using the JBN160 oligonucleotide, a segment 
encoding Pro116 to Gln206 was deleted from pES147. 
pJB114 (CPY-abcD-∆207-297). Using the JBN161 oligonucleotide, a segment 
encoding Pro207 to Asn297 was deleted from pES147. 
 
pKK117 and pKK129, expression vectors for PrA*-HA and PrA*-Ab-HA, 
respectively. A 2.1-kb fragment was amplified from pES163 (Spear and Ng, 2005) by 
Vent polymerase-directed PCR (New England Biolabs, Beverly MA) using KKN71 
and T3 primers, digested with XhoI, and purified. In parallel, a 0.5-kb fragment was 
amplified from pES163 using primers T7 and 5’-phosphorylated KKN72, digested 
with NotI and purified. These fragments were inserted into pRS316 (Sikorski and 
Hieter, 1989) create pKK117. Next, a N308Q mutation was introduced to eliminate 
the “B” glycosylation site. Using pKK117 as a template, the T3 and N537 primers 
amplified a 1.9 Kb fragment, digested with XhoI, and purified. A 0.7-kb fragment was 
amplified from pKK117 using primers T7 and N538, digested with NotI, and purified. 
These fragments were inserted into pRS316 to generate pKK129. 
 
pKK210, an expression vector for CPY*-abcD-D482-532. First, to create pAS68 
carrying CPY*-ABCD-D482-532, A 2.2-kb fragment was amplified from pDN436 
(pRS315-CPY*-ABCD-HA) using T7 and N572 primers, digested with EagI, and 
purified. In parallel, 0.6-kb fragment was amplified from pDN436 using T3 and N573 
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primers, digested with SalI, and purified. These fragments were inserted into pRS316 
to generate plasmid pAS78, which expresses CPY*-ABCD-D482-532. Next, a 2.0 kb 
SacI-BglII fragment from pES147 (Spear and Ng, 2005) was used to replace the 
analogous fragment in pAS78 to produce pKK210. 
 
pKK247, an expression vector for PrA-HA. The PEP4 gene was amplified from 
purified genomic DNA (strain W303a) by PCR with primers KKN274 and KKN275, 
digested with ClaI, and purified. This was used to replace the ClaI fragment in 
pKK117 to create plasmid pKK247. 
 
2.2.4. Yeast genomic DNA extraction 
 
Reagents are from Yeast DNA Extraction Kit (Thermo Scientific). Prepare 10 mL 
overnight yeast culture and pellet the cells 4,000 rpm for 5 minutes. Resuspend cells 
in 800 μL Y-PER buffer and incubate at 65℃ for 10 minutes. Pellet cells at 14,000 
rpm for 1 minute and discard supernatant. Add 400 μL DNA Relasing Reagent A and 
B each, mix gently with cells and incubate at 65℃ for 10 minutes. Add 200 μL 
Protein Removal Reagent, invert to mix, and pellet cells at 14,000 rpm for 5 minutes. 
Transfer supernatant to a new tube and mix with 600 μL isopropanol and gently. Spin 
at 14,000 rpm for 10 minutes and remove supernatant. Add 1.5 mL ice cold 70% 
ethanol and mix gently. Spin at 14,000 rpm for 1 minutes and remove ethanol. Air dry 




2.3. Biochemistry methods 
 
2.3.1. Antibody used in this study 
 
Anti-HA (HA.11) was purchased from Covance Research Products. HA-probe (F-7): 
sc-7392 was purchased from Santa Cruz Biotechnology, Inc. Anti-Kar2p and 
anti-Sec61p antibodies were provided by P. Walter (University of California, San 
Francisco, San Francisco, CA). Anti-CPY antibody was provided by Reid Gilmore 
(University of Massachusetts, Worcester, MA). 
 
2.3.2. TCA precipitation of yeast whole cell lysate 
 
Collect 2 OD600 of cells in a 2 mL screw cap tube, pellet cells at 14,000 rpm for 1 
minute and remove supernatant. Resuspend cells in 1 mL of 10% TCA. Cells were 
homogenized by the addition of 0.5 mL of 0.5-mm zirconium beads and agitated at 
full speed on a vortex mixer for 30 seconds at RT followed by 5 minute incubation on 
ice. This was repeated once. The supernatant was transferred to a fresh tube. The 
beads were washed once with 0.4 mL 10% TCA and combined with the saved 
supernatant. After centrifugation at 14,000 rpm for 15 minutes at 4℃, the TCA 
precipitate pellet was resuspended TCA suspension buffer (100 mM Tris-HCl, 3% 
SDS, pH 11.0) to achieve a final whole-cell lysate concentration of 0.04 OD600/μL 
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and heated to 100℃ for 10 minutes. Pellet insoluble debris at 14,000 rpm for 10 
minutes at 4℃, and transfer supernatant to a new collection tube. The whole cell 
lysate in TCA resuspension buffer can be stored at -20℃, or immediately analyzed by 
western blot. 
 
2.3.3. Western blot of yeast proteins 
 
Yeast protein samples (in TCA resuspension buffer or other buffers) equivalent to 0.2 
OD600 of whole-cell lysate were analyzed by SDS-PAGE. Proteins were transferred 
onto a nitrocellulose membrane at 4℃ at constant I = 300 mA for 75 minutes. Block 
membrane in 30 mL 5% non-fat milk in PBST buffer (137 mM NaCl, 2.7 mM KCl, 
10 mM Na2HPO4, 2 mM KH2PO4, 0.1% Tween-20, pH 7.4) (blot buffer) at RT for 30 
minutes. Discard the blot buffer, add 30 mL blot buffer containing primary antibody 
(1:10000 dilution) and shake at 75 rpm for 2 hours at RT or 4℃ overnight. Discard 
primary antibody solution and rinse blot with diH2O. Wash the membrane twice with 
PBST buffer for 13 min at RT. Add 30 mL blot buffer containing secondary antibody 
(1:10000 dilution) and shake at 75 rpm for 1 hour at RT. Discard secondary antibody 
solution and rinse blot with diH2O. Wash the membrane three times with PBST buffer 
for 10 min at RT. Protein signal was visualized by enhanced chemiluminescence 
according to manufacturer’s protocols (SuperSignal West Pico substrate, Pierce 
Biotechnology, Rockford, IL). The membrane can be stripped by incubating in 30 mL 
stripping buffer (100 mM glycine, pH 2.7) at 60℃ for 20 minutes followed by another 
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20 minute shaking at RT, and probed with another primary antibody again. 
 
2.3.4. Cycloheximide-chase analysis 
 
Strains were grown to log phase in synthetic complete media lacking the appropriate 
component for plasmid selection. Cell concentration (in OD600) was measured, and 
cycloheximide was added to the media to achieve a final concentration of 200 μg/mL. 
Cells were collected in 10% TCA at different time points, followed by standard TCA 
precipitation and western blot. 
 
2.3.5. Cell labeling and immunoprecipitation 
 
Cells were grown to mid log phase and 3 OD600 units of cells were pelleted and 
resuspended in 0.9 mL of SC media lacking methionine and cysteine. After 30 
minutes of incubation at the appropriate temperature, 150 µCi of [35S]Met/Cys 
(Pro-mix; Amersham Pharmacia Biotech) is added to cells for 10 minutes. A chase 
was initiated by adding cold methionine/cysteine to a final concentration of 2 mM. 
Cell labeling/chase was terminated by the addition of 100% TCA to a final 
concentration of 10%, followed by standard TCA precipitation. 
 
40 µL of the lysate in TCA resuspension buffer was added to 560 µl IPS II (13.3 mM 
Tris-HCl, 150 mM NaCl, 1% Triton X-100, 0.02% NaN3, 1mM PMSF, 1 µL protease 
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inhibitor cocktail; Sigma-Aldrich, pH 7.4) and the appropriate antiserum. After 2 hour 
incubation at 4℃, the sample was centrifuged for 15 minutes at 18,000 g and the 
supernatant transferred to a fresh tube containing protein A-Sepharose beads. The 
tube was rotated for 1 hour and washed three times with IPS I (0.2% SDS, 1% Triton 
X-100, 20 mM Tris-HCl, 150 mM NaCl, 0.02 % NaN3, pH 7.4) and once with TBS 
(20 mM Tris-HCl, 150 mM NaCl, pH 7.4). 
 
Immunoprecipitated proteins were eluted with gel sample buffer, separated by gel 
electrophoresis. SDS-PAGE gels were exposed to phosphor screens for 24 to 48 hours. 
Exposed screens were scanned using the TyphoonTM phosphorimager and quantified 
using ImageQuantTM TL software (GE Healthcare Life Sciences, Uppsala, Sweden). 
All data plots reflect three independent experiments with the standard error of the 
mean (SEM) indicated as error bars. Representative gel images from single 
experiments are shown in the figures. 
 
2.3.6. Yeast microsome preparation and native co-immunoprecipitation 
 
Strains were grown to log phase in synthetic complete media lacking the appropriate 
component for plasmid selection. 50 OD600 equivalents of cell culture were harvested 
by centrifugation at 3,000 g for 5 minutes at RT, washed twice in ice-cold water, and 
resuspended in 1 mL TN buffer (50 mM Tris-HCl, 50 mM NaCl, pH 7.4) containing 2 
mM PMSF and 1.5% Protease Inhibitor Cocktail (Sigma P8215). Cell disruption was 
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performed by bead beating (0.5 mm zirconium) on a vortex mixer 5 x 30 seconds, 
with 5 minutes on ice between each step. The following steps were all carried out at 
4℃. The supernatant was collected and pooled with 2x bead wash with 1 mL TN 
buffer. The supernatant from a low speed spin at 800 g for 5 minutes was subject to 
ultracentrifugation at 30,000 g for 30 minutes to collect microsomes. The pellet was 
solubilized by adding 0.5 mL Tris-IP buffer (TN buffer containing 1% Triton X-100, 
15% glycerol, and 2 mM PMSF) and incubated on a rotator for 2 hours. The lysate 
was clarified by centrifugation at 30,000 g for 10 minutes and supernatant was 
transferred to a new collection tube. 
 
20 µL portion of microsome fraction was combined with 500 µL of Tris-IP buffer, 5 
µL anti-HA conjugated agarose beads, and incubated at 4℃ with rocking for 2 hours. 
The beads were washed gently three times in ice-cold TN buffer containing 1% Triton 
X-100, and once in ice-cold TN buffer. Proteins were eluted from the beads by mixing 
with 10 µL 2x SDS-PAGE loading buffer (100 mM Tris-HCl, 4% SDS, 20% glycerol, 
0.2% bromophenol blue, pH 6.8) without DTT and boiled for 5 minutes. Supernatants 
were transferred to a fresh tube, DTT added to 100 mM, and boiled for another 5 
minutes. Protein samples were resolved by SDS-PAGE followed by analysis using 
western blot. 
 




Microsome fraction was prepared as described above (50 OD600 scale) but in the 
absence of protease inhibitors, and solubilized in 0.5 mL Tris-IP buffer lacking 
protease inhibitors. 10 µL of the lysate was combined with 90 µL of ice-cold PBS 
buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4) 
containing freshly added trypsin at 5.0 µg/mL. After incubation at 4℃ for different 
time points indicated in figures, 11.1 µL 100% TCA was added to the solution to stop 
the reaction. Proteins were precipitated by centrifugation at 18,000 g for 20 minutes, 
resuspended in 10 µL TCA resuspension solution and boiled for 10 minutes. Samples 
were mixed with 10 µL 2x SDS-PAGE loading buffer with DTT, and boiled for 
another 5 min, followed by western blot. 
 
2.3.8. Preparation of yeast proteins for mass spectrometry 
 
Strains were grown to late-log phase in synthetic complete media lacking the 
appropriate component for plasmid selection. 4000 OD600 equivalents of cell culture 
were harvested by low speed centrifugation at 3,000 g for 10 minutes and washed 
once in ice-cold water. Cells were resuspended in 100 mL spheroplasting buffer (10 
mM KH2PO4, 40 mM K2HPO4, 1.4 M sorbitol, pH 7.5) containing 40 mg 
zymolyase-20T and incubated at RT for 90 minutes. Spheroplasts were collected by 
centrifugation at 3,000 g for 5 minutes at 4℃, and resuspended in 200 mL ice-cold 
TN buffer containing 1 mM PMSF. Spheroplasts were homogenized on ice in a 
Sartorius Potter S motorized homogenizer at 1,300 rpm with 15 strokes. The 
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supernatant from a low speed spin was subjected to ultracentrifugation at 30,000 g for 
30 minutes to pellet microsomes. Microsomes were solubilized by incubation in 20 
mL of Tris-IP buffer at 4℃ for 1 hour and insoluble material removed by 
centrifugation at 30,000 g for 10 minutes. 50 µL of anti-HA conjugated agarose beads 
were added to the supernatant and incubated rocked for 2 hours at 4℃. The beads 
were washed gently three times in Tris-IP buffer and once in TN buffer. Proteins were 
eluted from the beads by mixing with 20 µL 2x SDS-PAGE loading buffer (100 mM 
Tris-HCl, 4% SDS, 20% glycerol, 0.2% bromophenol blue, pH 6.8) without DTT and 
boiled for 5 minutes. The supernatant was transferred to another tube and boiled for 
another 5 minutes in 100 mM DTT. Protein samples were loaded and resolved by 
SDS-PAGE and visualized by Coomassie Blue staining. Proteins bands were excised 
from the gel and tryptic fragments were analyzed by MALDI-MS/MS Mass 
Spectrometry (National University of Singapore Proteins and Proteomics Centre). 
 
2.4. Cell biology and microscopy methods 
 
2.4.1. Indirect immunofluorescence 
 
Grow 3 mL cells to early log phase. 3. Fix cells by adding 37% formaldehyde to 
3.7% and rotate at 30℃ for 90 minutes. Pellet cells at 1,000 g for 5 minutes at 4℃. 
Wash cells with 5 mL ice-cold 0.1 M K3PO4, pH7.5 and resuspend cells gently in 90 
μL spheroplasting buffer (0.1 M K3PO4, 1.2 M sorbitol, pH7.5). Add 10 µL 10 mg/mL 
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zymolase-20T in spheroplasting buffer, tap to mix and incubate at RT for 10-15 
minutes. Pellet cells at 1,000 g for 3 minutes at RT and discard supernatant. Wash 
spheroplast twice with 1 mL spheroplasting buffer, and resuspend in 25 µL 
spheroplasting buffer. Add the spheroplast onto the well of microscopic slide 
pre-coated with 0.1% poly-lysine and incubate at RT for 10 minutes in a wet petri dish. 
Remove excess cells with Kimwipes. Wash the slide with ice-cold TBS buffer (50 
mM Tris-HCl, 150 mM NaCl, pH 7.4) for 3 minutes, ice-cold methanol for 6 minutes, 
ice-cold acetone for 30 seconds, and ice-cold TBS buffer again for 3 minutes. Remove 
all solution droplets and let the slides air dry. Add 30 µL blocking buffer (5% non-fat 
milk, 0.1% Tween-20 in TBS buffer) onto each well, incubate at RT for 30 minutes in 
a wet petri dish and wash with TBS for 10 minutes. Add 30 µL blocking buffer 
containing primary antibody (mouse anti-HA 1:500, rabbit anti-Kar2 1:1000 dilution) 
and incubate at RT for 90 minutes in a wet petri dish or at 4℃ overnight. Wash twice 
with 30 µL TBS buffer for 10 minutes. Add 30 µL blocking buffer containing 
secondary antibody (Alexa Fluor 488 goat anti-mouse 1:500, Alexa Fluor 594 goat 
anti-rabbit 1:1000 dilution) and incubate at dark at RT for 90 minutes in a wet petri 
dish. Wash twice with 30 µL TBS buffer for 10 minutes. Add 3 µL of mixed mounting 
medium (0.05 µg/mL DAPI, 1 mg/mL p-phenylenediamine, 10% PBS buffer, 90% 
glycerol, pH 9.0). Apply cover slip and seal with clear nail polish. Slides can be stored 
at -20℃ in a dry and dark container or analyzed by confocal microscopy immediately. 
 




Imaging of cells in this study was performed using polyclonal rabbit anti-Kar2p and 
HA.11 mAb (Covance) as primary antibodies and Alexa Fluor 488 goat anti-mouse 
and Alexa Fluor 594 goat anti-rabbit (Invitrogen, Carlsbad, CA) as secondary 
antibodies. Cells were visualized using Zeiss LSM 510 META inverted microscope 
(Carl Zeiss MicroImaging, Thornwood, NY) with a Plan-Apochromat 100x Ph3 
objective (1.4 NA; Carl Zeiss MicroImaging). Image acquisition was performed using 
standard PMT with LSM 510 (Carl Zeiss MicroImaging). Images were archived using 
LSM 5 Image Examiner (Carl Zeiss MicroImaging) and Adobe Photoshop 7.0 (Adobe 
Systems, San Jose, CA). No additional software adjustments were performed on 








Quality control pathways monitor protein folding and assembly throughout the cell. 
Although generally poorly understood, the best-described systems are those of the 
endoplasmic reticulum (ER). ER quality control (ERQC) describes an assortment of 
mechanisms that, collectively, retains unfolded or unassembled proteins and targets 
irreversibly misfolded proteins for destruction through the appropriate ER-associated 
degradation (ERAD) pathway. For most molecules, ER quality control serves to 
prevent their transport during the folding process. Once folding is complete, intrinsic 
export signals guide their transport via cargo sorting receptors concentrated at and in 
the membranes of ER exit sites marked by COPII coat proteins (Sato and Nakano, 
2007). The framework of ERQC for luminal glycoproteins in budding yeast is 
conserved except for lack of a canonical CNX/CRT cycle. Like its mammalian 
counterpart, the yeast ERAD-L pathway (for turnover of misfolded luminal proteins) 
is centered on the Hrd1p E3 ligase and its immediate partner Hrd3p (Gardner et al., 
2000; Gauss et al., 2006b). Hrd1p-Hrd3p heterodimer organizes a complex of 
membrane associated factors that process substrates for degradation by the 26S 




For substrate recognition in the ER lumen, the structure of carbohydrate chains is 
essential. Recently, a subsequent and key processing step was proposed and confirmed 
experimentally (Clerc et al., 2009; Hirao et al., 2006; Olivari et al., 2006). Htm1p 
(EDEM in mammals) cleaves a single mannose residue from the C branch of the 
Man8GlcNAc2 glycan to expose a terminal α1,6-linked mannose. Remarkably, this 
moiety turns out to be the ligand for the substrate “proof-reading” factor Yos9p (Quan 
et al., 2008). Even with these important revelations, the mechanism was incomplete. 
Analyses of the model substrates CPY* and PrA* demonstrated that only single, 
specific glycans can signal ERAD (Kostova and Wolf, 2005; Spear and Ng, 2005). 
This suggested the requirement of additional determinants in the polypeptide chain. 
 
In this chapter, I performed systematic analyses of CPY* and PrA* to understand the 
signals recognized by the ERAD-L system. The study revealed that ERAD-specific 
glycans are positioned at peptide determinants sensitive to local and long-range 
perturbations affecting the structure of the protein. In correctly folding proteins, the 
ERAD determinant incorporates into the native structure to silence the degradation 
signal. In misfolded proteins, the determinant remains unfolded and recruits the 
molecular chaperone BiP/Kar2p, a factor required for ERAD. Persistence of this state 
allows the ER mannosidases Mns1p and Htm1p to modify the glycan and form the 
complete bipartite degradation signal recognized by Hrd1p complex (Clerc et al., 






3.2.1. A bipartite signal targets misfolded glycoproteins to ERAD 
 
CPY* and PrA* are well-studied model glycan-dependent ERAD substrates with 
known crystal structures for their folded counterparts carboxypeptidase Y (CPY) and 
proteinase A (PrA) (Aguilar et al., 1997; Endrizzi et al., 1994; Finger et al., 1993). 
The prc1-1 (CPY*) allele contains a missense mutation that results in the G255R 
change at the core of the folded protein. PrA* differs from wild type by a short 
deletion near its N-terminus. These simple lesions cause complete folding failures that 
expose signals recognized by ERAD (Finger et al., 1993). Of what is currently known, 
only the C-terminal glycan of CPY* is required (Kostova and Wolf, 2005; Spear and 
Ng, 2005). The other three do not contribute. Similarly, PrA* relies on a single glycan, 
but near its N-terminus (Spear and Ng, 2005). The context specificity suggested that 
additional determinants embedded within the polypeptide chains, when unfolded, 
contribute to the recognition code. Short sequence-based signals or “degrons” have 
been identified for the ER-associated degradation of the folded proteins IgM heavy 
chain and cyclooxygenase (Mbonye et al., 2006; Shapira et al., 2007). By extension, if 
similar elements work with the glycan signals, disrupting them should destroy the 
signal. 
 












Figure 3.1. Deletion variants of CPY* and PrA* are degraded efficiently in 
Wild-type cells. (by Kazue Kanehara) 
(A) Schematic representation of variants showing positions of individual deletions 
under each diagram. Amino acid numbers are ordered with the initiator methionine 
designated as "1". CPY* and PrA* deletion variants in this series carry only their 
respective signal glycan as indicated by the extensions –abcD and –Ab, respectively 
(upper case signifies a functional glycosylation site and lower case a mutated site; see 
Figure 3.3 for the positions of each glycan). An asterisk indicates the position of the 
CPY* G255R mutation. PrA* lacks the sequences Leu55 through Tyr91 of PrA 
(Finger et al., 1993). Signal sequences are shaded green, pro-domains shaded yellow, 
and HA-epitope tags shaded blue. Amino acid numbers in PrA* variants are based on 
their position on PrA*, which lacks the Leu55 to Tyr91 segment of PrA (See Figure 
3.3B). 
(B) Wild type cells expressing CPY*-abcD variants or PrA*-Ab variants were pulse 
labeled for 10 min and chased for the times indicated. Proteins were 
immunoprecipitated using monoclonal HA antibody from detergent lysates and 
resolved by SDS-PAGE. Turnover rates were quantified by phosphorimager analysis. 





and PrA*. The test molecules carry only their respective ERAD signal glycans 
(designated CPY*-abcD and PrA*-Ab, respectively) so that any effects can be 
attributed to them specifically. As shown in Figure 3.1, none of the variants are 
impaired for ERAD compared to full-length controls. Indeed, the turnover rates for 
most deletion constructs are slightly increased. This effect is likely attributable to their 
reduced sizes compared to control. These data suggest ERAD determinants do not 
integrate sequence-specific elements that would explain the stringent positional 
effects. The result is not entirely surprising since it has been proposed that a 
conformational sensor might be needed in addition to the glycan timer to differentiate 
ER resident glycoproteins (Helenius and Aebi, 2004). We next queried whether the 
determinant might have a structural basis. For this, the three dimensional structure of 
mature CPY was surveyed for possible clues. 
 
Depicted in Figure 3.2 is a ribbon representation of the CPY crystal structure with the 
positions of glycan asparagines indicated (Endrizzi et al., 1994). Notably, the D 
“signal” glycan is positioned on the end of an 11-stranded β-sheet, arranged mostly in 
parallel. Because of this configuration, stability of the β-sheet and vis-à-vis, the local 
environment of the D glycan, can be sensitive to the overall packing of the 
polypeptide. Thus, both short and long range folding failures could affect the correct 
ordering of the segment. The A, B, and C glycans, by contrast, are located on surface 
loops that form fewer contacts with other parts of the polypeptide. Because unfolded 







Figure 3.2. Ribbon diagram of mature CPY. 
The positions of glycans A, B, and C are shown in blue and glycan D is shown in 
purple. Orange spheres mark Gly255, which is mutated to Arg in CPY*. Amino acid 
numbers are ordered with the initiator methionine at position 1. The diagram was 
generated using the PyMOL 0.99rc6 software (Delano Scientific, LLC) with 





ordered structures, if formed around these glycans in CPY*, may explain their failed 
recognition by ERAD. 
 
To begin testing our hypothesis, we wished to determine whether peptide segments 
directly adjacent to signal glycans combine to form good substrates for ERAD. For 
this, mini CPY and PrA variants were constructed consisting only of the respective 
signal glycans and immediate peptide segments. The N-terminal 348 residues of 
proCPY were deleted to create CPY∆2 (a 176 residue glycoprotein after signal 
sequence cleavage) and the C-terminal 251 residues of PrA* were deleted to create 
PrA*-∆155-405 (a 104 residue glycoprotein after signal sequence cleavage) (Figure 
3.3, A and B). Cycloheximide chase experiments were performed to measure their 
turnover in wild type and strains deficient for the Hrd1p ERAD pathway. Both 
variants degraded rapidly in wild type cells and strongly stabilized in ∆hrd1 and 
∆htm1 strains (Figure 3.3, C and D). These mutants test for requirements of the Hrd1p 
complex and glycan remodeling functions of ERAD, respectively (Bordallo et al., 
1998; Carvalho et al., 2006; Clerc et al., 2009; Gardner et al., 2001). These data 
demonstrate that luminal ERAD requires only the glycan and their local segments for 
recognition. Importantly, CPY∆2, which lacks the G255R “star” mutation, shows that 
the loss of tertiary interactions through the large deletion is sufficient to activate the D 
glycan domain to function as an ERAD determinant. By contrast, the reciprocal 
variant that eliminates the D glycan region, called CPY∆1, renders a misfolded 





Figure 3.3. Signal glycans and adjacent peptide segments are sufficient to signal ERAD 
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Figure 3.3. Signal glycans and adjacent peptide segments are sufficient to signal 
ERAD. 
(A) Schematic representation of preproCPY, CPY*, CPY∆1 and CPY∆2. 
Carbohydrates are represented by branch symbols. The asterisk indicates the CPY* 
G255R mutation. Signal sequences are shaded green, pro-domains shaded yellow, and 
HA-epitope tags shaded blue. 
(B) Schematic representation of preproPrA, PrA* and PrA*-∆155-405. Carbohydrates 
are represented by branched symbols, A and B indicate Asn144 and Asn345 
respectively. Shadings indicate the same elements as in panel A. 
(C) Wild type, ∆hrd1 or ∆htm1 cells expressing CPY∆2 were grown to log phase and 
cycloheximide was added to begin the chase for times shown. Whole cell lysates were 
prepared and proteins resolved by SDS-PAGE. Substrates were detected on 
immunoblots using the anti-HA monoclonal antibody (upper panels). Blots were 
reprobed with anti-Sec61p antisera as a loading control (lower panels). The arrowhead 
marks the position of a higher molecular weight form of CPY∆2 that accumulates in 
the ERAD mutants. This form is most likely due to O-mannosylation, previously 
observed for other substrates (Vashist et al., 2001). 
(D) Turnover of PrA*-∆155-405 in wild type, ∆hrd1, and ∆htm1 cells was analyzed as 




Interestingly, the CPY C-terminal domain is sufficient to target non-substrate 
molecules to ERAD. When appended to dihydrofolate reductase, the Hrd1p pathway 
degrades the fusion protein in a glycan-dependent fashion (Carvalho and Rapoport, 
personal communication). 
 
Aebi and coworkers demonstrate that the Man7GlcNAc2 structure generated by 
Htm1p is needed to trigger ERAD in budding yeast (Figure 1.4) (Clerc et al., 2009). 
The Yos9p receptor recognizes the terminal α1,6-mannose residue found in this 
structure (Quan et al., 2008). Other glycan structures containing the moiety (e.g., the 
N-linked Man5GlcNAc2 glycans in ∆alg3 strain) can also signal ERAD (Jakob et al., 
1998b). The requirement for an unfolded local segment in our study raises the 
possibility that it combines with the glycan to form a bipartite signal read by ERAD. 
Alternatively, it could act upstream to recruit Htm1p to modify adjacent glycans and 
that it is this glycan structure alone that mark proteins for destruction. To distinguish 
between these possibilities, we compared the stability of folded endogenous proteins 
in wild type and ∆alg3 strains. Because all N-linked glycans in ∆alg3 cells contain the 
terminal α1,6-mannose carbohydrate, all glycoproteins would be subject to ERAD 
should the glycan act alone as the signal. As shown in Figure 3.4 (panels A and B), 
wild type CPY and PDI are as stable in the ∆alg3 strain as wild type. PDI is 
particularly notable because it is an ER glycoprotein continuously exposed to the 
ERAD machinery. As a control, the HTM1 requirement for CPY* degradation is 





Figure 3.4. Glycan structure alone is not sufficient for ERAD substrate recognition 
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Figure 3.4. Glycan structure alone is not sufficient for ERAD substrate 
recognition. 
(A and B) Wild type and Δalg3 cells were pulse labeled for 10 min and chased for 
times indicated. Proteins were immunoprecipitated from detergent lysates using 
polyclonal antisera and resolved by SDS-PAGE. Protein turnover was quantified by 
phosphorimager analysis. 
(A) Relative CPY turnover is plotted with representative phosphorimages shown. The 
Δalg3 mutant exhibits minor underglycosylation of proteins (Jakob et al., 1998). The 
positions of mature CPY bearing 4 glycans (mCPY) and 3 glycans (-1 mCPY) are 
indicated. 
(B) Protein disulfide isomerase (PDI) stability was analyzed as described in panel A. 
(C and D) Turnover of CPY* variants were compared in wild type, Δhtm1, Δalg3, and 
Δalg3Δhtm1 strains by metabolic pulse-chase analysis as in panels A and B. 
(C) Degradation of CPY*-abcD and (D) the non-glycosylated variant CPY*-abcd. 





(Figure 3.4C). The effect is also restricted to misfolded glycoproteins since the 
turnover of a non-glycosylated form of CPY* is neither accelerated in ∆alg3 strain 
nor further stabilized in ∆htm1 mutant (Figure 3.4D). These data show that signal 
glycans require the presence of adjacent unfolded peptide segments for recognition by 
ERAD. 
 
3.2.2. Local conformational perturbations activate non-signal glycans for ERAD 
 
In CPY*, are non-signal glycans inactive because they reside adjacent locally ordered 
structures? If so, deliberately disturbing the structures might create active ERAD 
signals. To test this idea, the segments directly adjacent to the A, B, and C glycans of 
CPY* were individually disrupted with 12 residue deletions (Figure 3.5, upper panels). 
These glycans do not participate significantly in ERAD signaling (Kostova and Wolf, 
2005; Spear and Ng, 2005). To assess whether the lesions are indeed structurally 
disruptive, we applied a test that uses ERAD as the readout. For this, identical 
deletions were introduced in parallel in preproCPY and analyzed for their recognition 
by ERAD. ERAD of misfolded CPY is characterized by ER retention (lack of 
processing to the slower migrating p2 Golgi form, as seen in Figure 3.4A) and rapid 
degradation (Stevens et al., 1982). As shown in Figure 3.5 lower panels, the absence 
of a p2 species followed by their rapid turnover demonstrates that the lesions are 







Figure 3.5. Glycan-proximal lesions are structural disruptive 
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Figure 3.5. Glycan-proximal lesions are structural disruptive. 
Surface rendering of segments adjacent to glycans A, B, and C of folded CPY using 
the PyMOL software described in Figure 3.2. β-strands, loops and α-helixes depicted 
in yellow, green, and red, respectively. Glycosylation sites are depicted in blue. 
(Lower panels) Wild type cells expressing CPY deletion variants were pulse labeled 
for 10 min and chased for the times indicated. Proteins were immunoprecipitated 
using monoclonal HA antibody from detergent lysates, resolved by SDS-PAGE, and 





Figure 3.6. Glycan-proximal lesions can generate artificial ERAD determinants. 
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Figure 3.6. Glycan-proximal lesions can generate artificial ERAD determinants. 
(A) The turnover of CPY* single-glycan variants in wild type and Δhrd1 cells were 
analyzed by pulse-chase analysis as described in Figure 3.5. Decay was quantified by 
phosphorimager analysis and plotted with error bars indicating the SEM of three 
independent experiments. Representative phosphorimages of each experiment are 
shown. 





Next, the deletions were introduced into the corresponding CPY* single-glycan 
variants. Unlike CPY*-abcD, variants containing only the A, B, or C glycan are not 
degraded by ERAD (Kostova and Wolf, 2005). As shown in Figure 3.6, all six 
variants are ERAD substrates dependent on HRD1 and HTM1. These experiments 
show that functional ERAD determinants can be created with non-signaling glycans 
by introducing structurally disruptive lesions into adjacent segments. 
 
Because of the observed positional effects, we next asked if glycan proximity 
influences formation or accessibility of an ERAD signal. For this, we duplicated the 
region surrounding glycosylation site B (Figure 3.7A, shaded red) to precisely replace 
the D glycan domain. Enough of the region was duplicated to support the formation of 
any local secondary structures near the glycan. If proximity to protein boundaries is a 
critical factor, transposing the segments around an ERAD-inactive glycan to a 
favorable position might activate it. The resulting variant, CPY*-abcB, though 
retained in the ER (Figure 3.7C), is stable in wild type cells showing that glycan 
proximity alone is not sufficient to generate a destruction signal in a misfolded protein 
(Figure 3.7B, CPY*abcB). Directly perturbing structure of the inactive site by 
deleting adjacent sequences, however, produced an excellent ERAD substrate (Figure 
3.7B, CPY*-abcB-∆482-532). 
 
These data show that ERAD-inactive glycan sites can be coaxed into mimicking 
ERAD signals by deliberately introducing structurally disruptive lesions into adjacent 
segments. In agreement with earlier experiments, the primary sequences surrounding 






Figure 3.7. Glycan proximity is not a major determinant of substrate recognition 
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Figure 3.7. Glycan proximity is not a major determinant of substrate 
recognition. 
(A) Schematic representation of CPY*, CPY*-abcB and CPY*-abcB-∆482-532. The 
segment encompassing Ile88 to Phe251 of CPY* is shaded red. This segment is 
transposed to replace the C-terminus of CPY*-abcD to create CPY*-abcB. 
CPY*-abcB-∆482-532 differs from CPY*-abcB by a Val482 to Phe532 deletion. 
(B) Turnover of CPY*-abcB and CPY*-abcB-∆482-532 in wild type cells and 
CPY*-abcB-∆482-532 in ∆hrd1 cells were measured and plotted as described in 
Figure 3.6A. 
(C) Intraceullar localization of CPY*-abcB performed by indirect 
immunofluorescence using anti-HA (left) and anti-Kar2p antibodies (middle). The 




3.2.3. The CPY ERAD determinant is recognized by the BiP/Kar2p chaperon 
 
The studies thus far demonstrate that substrate recognition involves peptide segments 
adjacent signaling glycans. To better understand how it is recognized, we applied a 
biochemical approach to probe the determinant. The whole length of the CPY* 
molecule is sensitive to trypsin digestion compared to the compactly folded CPY 
(Finger et al., 1993). We reasoned that application of the assay under conditions 
preserving protein-protein interactions might reveal regions recognized by ERAD 
factors. In turn, this information could be used to purify and identify the factors. 
 
A microsomal fraction was prepared from cells expressing HA-tagged CPY* or CPY. 
Membranes were solubilized in detergent buffer under physiological conditions and 
subjected to limited trypsin digestion. Aliquots collected at various intervals were 
analyzed by immunoblotting for CPY. As shown in Figure 3.8A, proCPY is resistant 
to trypsin digestion during the time course as reported previously (Finger et al., 1993). 
By contrast, digestion of CPY* (the CPY* substrate includes the pro region of CPY) 
generates several fragments by 5 min with the most prominent migrating near the 25 
kDa marker. Unlike other fragments, it persists during the time course suggesting 
protection by bound factors. The protected fragment represents the CPY* C-terminus 
due to the location of the epitope tag. Probing the blot using a polyclonal antiserum 
generated against proCPY, showed a similar pattern (except with higher background) 
so using the HA antibody did not limit the analysis (data not shown). Intriguingly, the 
protected fragment represents the area surrounding the D glycan—the region 
determined to be the CPY* ERAD determinant. We next tested whether the D glycan 






Figure 3.8. The peptide segments adjacent the CPY* signal glycan are recognized 
by the chaperone BiP/Kar2p 
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Figure 3.8. The peptide segments adjacent the CPY* signal glycan are recognized 
by the chaperone BiP/Kar2p. 
(A) Microsomal fractions were prepared from ∆cue1∆pep4∆prc1 cells expressing 
CPY-HA, CPY*, and CPY*-ABCd. Membranes containing the substrates solubilized 
in detergent under non-denaturing conditions and digested with 5 µg/mL trypsin for 
the times indicated. The proteins were separated by SDS-PAGE and detected on 
immunoblots with the anti-HA antibody. Arrowheads indicate the positions of 
protease-resistant fragments. 
(B) CPY∆2 expressed in ∆cue1∆pep4∆prc1 cells was immunopurified from 
microsomes under native conditions. Eluted proteins resolved by SDS-PAGE and 
visualized by Coomassie Brilliant Blue (left lane). The procedure was performed in 
parallel using cells lacking CPY∆2 as a control (right lane). The open arrowhead 
shows the position of the modified form of CPY∆2. 
(C) CPY*, CPY∆1, and CPY∆2 expre ssed in ∆cue1∆pep4∆prc1 cells were 
immunoprecipitated from detergent lysates under were native conditions, resolved by 
SDS-PAGE, and immunoblots probed for the substrate (middle panel) and BiP/Kar2p 
(upper panel). The lower panel shows the load (1/20 of the total of each lysate probed 




variant, which lacks only the D glycan. As shown in Figure 3.8A (right), a nearly 
identical pattern was obtained except that the protected fragment migrated slightly 
faster at 23 kDa—the size expected without the glycan. These data suggest that the 
CPY* ERAD determinant specifically recruits protein factors and recruitment does 
not depend on the glycan. 
 
To identify factors associated with the CPY* ERAD determinant, the CPY∆2
substrate was immunopurified from a microsomal fraction. CPY∆2 was chosen 
because it encompasses the trypsin-protected segment and is a bona fide ERAD 
substrate of the Hrd1p pathway (Figure 3.3). Eliminating other parts of CPY* enables 
the purification of factors that are most relevant for ERAD. Purified complexes were 
resolved by SDS-PAGE (Figure 3.8B). Strongly staining bands were excised as gel 
slices, digested with trypsin, and analyzed by mass spectrometry. A prominent band 
migrating above the 75 kD marker was identified as Kar2p (also known as BiP), a 
member of the Hsp70 family of chaperones (Table 3.1). In yeast, KAR2 mutants are 
defective in ERAD and caused substrates to aggregate (Kabani et al., 2003; 
Nishikawa et al., 2001). Other bands include the IgG heavy and light chains partially 
released from the resin, CPY∆2, and an in vivo modified form of CPY∆2 that 
migrates slower (Figures 3.3C and 3.8B). Minor bands include BiP/Kar2p degradation 
products and other proteins that appear to be contaminants. BiP/Karp2 was absent 
from control lysates (Figure 3.8B, “Vector” lane). 
 
To determine the binding specificity to the ERAD determinant, CPY*, CPY∆1, and 
CPY∆2 were immunoprecipitated under non-denaturing conditions and probed for 
BiP/Kar2p on immunoblots. As shown in Figure 3.8C, the ERAD substrates CPY* 
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Table 3.1. Peptide analysis of CPYΔ2-binding protein. 
 
The peptide sequences of Kar2p identified by mass spectrometry are summarized. 
Peptide position indicates the start and end point of the identified peptide within the 
sequence of Kar2p with the translation initiator methionine as position 1. Mr (expt) is 
the experimentally determined mass, and Mr (calc) is the calculated mass of the 
peptide. Delta represents the observed mass versus delta error. Miss indicates the 
number of missed trypsin cleavage sites, and the peptides identified column lists the 
actual sequence of the identified peptide. The ions score is -10*Log(P), where P is the 
probability that the observed match is a random event. Protein matches to NCBInr 
gi|6322426, Saccharomyces cerevisiae Kar2p. Nominal mass (Mr): 74480. Sequence 
coverage is 17%. 
 
Peptide position Mr (expt) Mr (calc) Delta Miss Peptides identified Ions score 
83 - 95 1512.76 1512.71 0.06 0 ITPSYVAFTDDER 92 
103 - 117 1671.92 1671.86 0.06 0 NQVAANPQNTIFDIK 89 
185 - 201 1887.04 1886.96 0.07 0 VTHAVVTVPAYFNDAQR 101 
218 - 233 1644.94 1644.87 0.06 0 IVNEPTAAAIAYGLDK 69 
327 - 344 2022.10 2022.02 0.08 0 IEIDSFVDGIDLSETLTR 114 
345 - 356 1465.84 1465.78 0.06 1 AKFEELNLDLFK 53 
391 - 402 1425.77 1425.71 0.06 0 VQQLLESYFDGK 62 
391 - 403 1553.87 1553.81 0.06 1 VQQLLESYFDGKK 36 
502 - 512 1196.70 1196.66 0.04 0 FELTGIPPAPR 58 
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and CPY∆2 coimmunoprecipitated similar amounts of the chaperone. By contrast 
CPY∆1, a deletion variant lacking the ERAD determinant, associated with BiP/Kar2p 
very poorly (though apparently absent in Figure 3.8C, longer exposures revealed a 
signal above the control, data not shown). Notably, CPY∆1 is a misfolded 
glycoprotein not degraded by ERAD (Spear and Ng, 2005). Taken together, these data 
show that BiP/Kar2p specifically binds the region of the CPY* ERAD determinant. It 
should be noted, however, that strong BiP/Kar2p binding alone is not sufficient to 
drive ERAD. The presence of the D glycan is critical. The non-glycosylated variant of 
CPY* which is not degraded by ERAD (Knop et al., 1996b) binds BiP as well as 
CPY* (data not shown). The identity of BiP/Kar2p at this site has other important 
implications. Structural and biochemical analysis established that the Hsp70 
chaperone family, and BiP/Kar2p specifically, bind peptide substrates in extended 
conformations (Fourie et al., 1994; Zhu et al., 1996). These data reinforce the 
evidence that the ERAD determinant is a glycan attached to a disordered structure. 
 
3.2.4. Substrate signaling domains act as reporters of protein misfolding 
 
The D glycan determinant is required for the ERAD of CPY*. However, it was not 
known whether its use is specifically associated to the G255R “star” mutation or 
reflects a universal signal for CPY misfolding. To answer this question, we introduced 
lesions at locations throughout CPY systematically. To attribute signaling to the D 
glycan domain, all mutants are variants of CPY-abcD (CPY lacking the A, B, and C 
glycans), which itself folds efficiently (Figure 3.11C). By pulse-chase analysis, all of 
the variants were degraded by the Hrd1p complex (Figure 3.9, panels A and B) 









Figure 3.9. The CPY ERAD determinant can detect lesions throughout the 
polypeptide. (by Kazue Kanehara) 
A systematic deletion series was constructed using CPY-abcD as was done for 
CPY*-abcD (see Figure 3.1). 
(A) Turnover profiles were determined for each variant in wild type and ∆hrd1 cells 
as described for Figure 3.1. The data represent 3 independent experiments with error 
bars reflecting the SEM. Representative images from phosphorimager scans of each 
experiment are shown. 




the polypeptide. The slightly less efficient degradation of CPY-abcD-∆482-532 (a 
C-terminal deletion) is likely due to the deletion being less structurally disruptive than 
the others. A similar variant, CPY*-abcD-∆482-532, differing only by its G255R 
“star” mutation, was degraded as efficiently as CPY* (Figure 3.1B). 
 
We next tested the sensitivity of the D glycan determinant in reporting less severe 
perturbations. CPY surface positions structurally distant from the D glycan site were 
selected for disruption (Figure 3.11A, mutations marked on the ribbon diagram). 
Non-conservative amino acid substitutions were first introduced into fully 
glycosylated CPY to assess their effects to folding and transport. Two alleles, G227R 
and I451R, did not affect maturation (Figure 3.10A). Three other mutations, S194K, 
C328P, and C351P, prevented maturation indicating defects in folding (Figure 3.10B). 
The mixed result was not unexpected because protein surfaces are more structurally 
tolerant to amino acid substitution than core regions (Cunningham and Wells, 1989; 
Lawrence et al., 2007). 
 
To assess the effectiveness of the glycan D determinant to report misfolding, the 
S194K, C328P, and C351P mutations were introduced singly into CPY-abcD. As 
shown in Figure 3.11B (left panels), all three variants were efficiently degraded by 
ERAD. Since these are novel CPY misfolding mutants, we tested whether other 
glycans could report on the lesions. For this, the mutations were introduced into 
CPY-ABCd, which lacks only the D glycan. In no case did the three glycans support 
ERAD (Figure 3.11B, right panels). The result was surprising because one mutation, 
S194K, is positioned only 4 residues away from the B glycan. Taken together, these 








Figure 3.10. Intracellular processing of CPY and PrA point mutants 
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Figure 3.10. Intracellular processing of CPY and PrA point mutants. 
CPY and PrA fully glycosylated variants were analyzed by metabolic pulse-chase (10 
min pulse) followed by immunoprecipitation and separation by SDS-PAGE. Although 
all variants carry C-terminal HA tags, it was necessary to express CPY variants in 
strains deleted of PRC1 (encodes CPY) and use anti-CPY antisera to visualize all 
recombinant forms because the CPY HA tag is proteolytically removed in the vacuole. 
(A and B) CPY variants. The positions of ER (p1), Golgi (p2), and mature vacuolar 
(m) forms are indicated. 
(C and D) PrA variants. The positions of ER (p1), Golgi (p2), and mature vacuolar (m) 
forms are indicated. 
(A) Δprc1 knockout cells expressing CPY-ABCD-G227R or CPY-ABCD-I451R. 
(B) Wild type cells expressing PrA-AB-N88D or PrA-AB-G233K. 
(C) Wild type cells expressing CPY-ABCD, CPY* or CPY-ABCD-S194K, and Δprc1 
knockout cells expressing CPY-ABCD-C328P or CPY-ABCD-C351P. 












Figure 3.11. The CPY and PrA signal glycans mark domains broadly sensitive to 
structural defects. 
(A) Ribbon diagram of the CPY structure showing position of the D glycan to 
introduced lesions. The D signal glycan site is in purple and the positions of mutated 
residues are in orange. 
(B) Misfolded CPY variants bearing only the D glycan (left panels) or bearing the A, 
B, and C glycans (right panels) were analyzed for degradation efficiency in wild type 
and ∆hrd1 strains as described in Figure 3.1. 
(C) CPY-abcD was pulse labeled for 10 min and chased for the times indicated. 
Proteins were immunoprecipitated using polyclonal CPY antisera (the strain lacks 
endogenous CPY) from detergent extracts and resolved by SDS-PAGE. 
(D) Ribbon diagram of the PrA structure showing the position of the A glycan (purple) 
to mutated residues (orange spheres). 
(E) PrA variants bearing only the A glycan (left panels) or only the B glycan were 




misfolding. Other glycan sites do not perform this function unless their attached 
segments are directly and severely altered. 
 
We next extended the analysis to PrA. In the context of the PrA* mutation (a 37 
amino acid deletion in its pro domain), the N-terminal A glycan signals ERAD while 
the C-terminal B glycan does not. Unlike CPY, folded PrA has a bi-lobed structure 
connected by single peptide segment (Figure 3.11D). Thus, it seemed possible that 
additional ERAD determinants might be employed if the domains could fold 
independently. Four non-conservative point mutations were introduced singly into 
wild type PrA. The G199K and I365R alleles caused misfolding while the N88D and 
G233K changes were benign (Figure 3.10, panels C and D). To assess how individual 
glycans contribute to ERAD signaling, we altered the singly glycosylated PrA-Ab and 
PrA-aB molecules with the folding disruptive mutations. In pulse-chase experiments, 
PrA-Ab-G199K was degraded efficiently by ERAD but PrA-aB-G199K was stable in 
both wild type and ∆hrd1 cells (Figure 3.11E, upper panels). This could be expected 
since the mutation, like that of PrA*, is located in the N-terminal lobe. The I365R 
mutation, located in the other lobe, did not generate the reciprocal pattern. The 
PrA-aB-I365R protein was efficiently degraded by ERAD showing that a B glycan 
determinant can be activated if folding is disrupted nearby (Figure 3.11E, lower right 
panel). Surprisingly, the A glycan determinant was just as effective even though it is 
located on the other lobe (Figure 3.11E, lower left panel). These data show that the A 
glycan determinant, like the D glycan signal of CPY, can function as a general 







Folded substrates of the ubiquitin-proteasome system (UPS) are recognized through 
signals displayed on protein surfaces (Hershko et al., 2000). Usually, the E3 ligases 
catalyzing ubiquitin attachment play the most direct role in recognition. Unfortunately, 
this basic concept is not easily applied to ERAD. Foremost, the stringency of ERAD 
must be calibrated. The ideal “sieve” should catch severely misfolded molecules but 
permit the passage of minor genetic variants as not to impede the evolutionary process. 
Proteins also have the potential to misfold in numerous ways so some features 
prominent in one form can be absent in another. Compounding the problem is the 
likelihood that many features found on actively folding proteins are also present on 
“misfolded” proteins. Lastly, the sheer number of potential substrates rules out a 
motif-based mechanism without putting structural constraints on proteins. With this 
view, it was difficult to envision how the ERAD mechanism can follow the UPS 
paradigm. However, indications of substrate signals abound. 
 
In budding yeast, different ERAD pathways screen misfolded substrates based on the 
topological location of lesions (Hill and Cooper, 2000; Huyer et al., 2004; Taxis et al., 
2003; Vashist and Ng, 2004). These observations implied that specific physical 
hallmarks are used for recognition. The strongest clues to the existence of actual 
degradation signals or “degrons” emerged from mutational studies of the CPY* model. 
Eliminating its glycans completely abolished degradation (Knop et al., 1996b).  The 
subsequent discovery of lectin-like ERAD factors firmly planted the idea that the 
glycans themselves can act as signals. One of the factors, Htm1p/Mnl1p (EDEM in 
mammals), is essential for the degradation of misfolded glycoproteins (Hosokawa et 
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al., 2001; Jakob et al., 2001; Nakatsukasa et al., 2001). It was originally proposed to 
act as a lectin-like receptor for ERAD (Hosokawa et al., 2003; Molinari et al., 2003). 
However, recent work has shown that Htm1p/Mnl1p is a mannosidase that converts 
the Man8GlcNAc2 structure to Man7GlcNAc2 by removing the terminal α1,2-linked 
mannose residue from the C-arm of the glycan (Clerc et al., 2009). This reaction 
leaves a new terminal mannose residue that is α1,6-linked, the ligand of the ERAD 
lectin-like receptor Yos9p (Quan et al., 2008). The combined activities of Mns1p 
(converts Man9GlcNAc2 to Man8GlcNAc2) and Htm1p/Mnl1p generate the glycan 
portion of the bipartite ERAD signal (Figure 1.4). By activating the signal for ERAD, 
these enzymes act sequentially as a molecular timer to differentiate “misfolded” 
proteins (Man7GlcNAc2) from folding intermediates (Man9GlcNAc2 and 
Man8GlcNAc2). 
 
The finding that only specific glycans on model substrates could act as signals 
suggested additional determinants embedded in the polypeptide chain. Thus, an 
understanding of the complete determinant is required before the mechanism of 
substrate recognition can be solved. The determinant itself - a single glycan attached 
to an unfolded segment - turned out to be deceptively simple given the strict context 
specificity of the glycan. The benefit of the design became clear as we sought to 
understand why other glycan sites in CPY* fail to signal. By considering the 
established principle that unfolded proteins can sustain extensive secondary structures 
(Dyson and Wright, 2004), we postulated that inactive glycans might be positioned in 
segments that maintain localized ordered structures. This notion was supported 
experimentally. Only when structurally disruptive lesions were introduced in direct 
proximity to non-signal glycans were they recognized by ERAD (Figure 3.6). These 
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results emphasize the idea that ERAD determinants play a specialized role in ER 
quality control. In the case of the D glycan, it is entirely dispensable for CPY’s normal 
function. It is not required for the maturation or transport of proCPY and eliminating 
the glycan actually increases its enzymatic activity (Winther et al., 1991). 
 
By incorporating protein disorder into the ERAD signal, the region harboring it 
effectively functions as a sensor that reports directly on local folding. If the 
determinant remains unfolded by the time it can be processed by Mns1p and Htm1p, 
the activated signal is displayed for the ERAD machinery. Our data show that 
glycoproteins use this mechanism, but in a more sophisticated way. The CPY D 
glycan appears to be positioned so formation of the local structure is dependent on the 
overall packing of the polypeptide (Figure 3.2). This would extend the reach of the 
sensor to include all long-range perturbations affecting tertiary structure. This 
mechanism was confirmed experimentally and its importance for quality control is 
underscored by the observation that other glycan sites fail to substitute in most 
instances (Figures 3.9 and 3.11). These data support the earlier proposal that the 
glycan timer mechanism might require an associated conformational sensor to spare 
ER resident proteins (Helenius and Aebi, 2004). Although the concept of an intrinsic 
sensor domain was not previously demonstrated, the structural basis of 
ordered/disordered segments in unfolded proteins is well documented. After tertiary 
structure disruption, the barnase protein continues to maintain secondary structures 
while chymotrypsin inhibitor 2 is largely devoid of ordered structures (Fersht and 
Daggett, 2002). Similarly, “intrinsically disordered proteins” make up a large family 
whose members have some or all of their peptide segments disordered in solution 
(Dyson and Wright, 2005). For some, assembly with partner proteins converts 
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disordered segments into folded structures, usually α-helixes. In principle, any domain 
containing a segment whose structure depends on the correct packing of the overall 
structure can be used as an ERAD folding sensor simply by attaching an N-linked 
glycan. 
 
The proposed mechanism, though remarkably simple, satisfies the broad requirements 
of ERAD. It supports a reliable disposal system for misfolded proteins and is tolerant 
for the emergence of minor genetic variants. This dynamic was observed even within 
the confines of this study. Misfolded forms were efficiently degraded (Figures 3.1, 3.9 
and 3.11) while variants bearing non-conservative changes, but not grossly misfolded, 
were transported and processed normally (Figure 3.10). By employing a single 
determinant independent of sequence, the mechanism places fewer structural demands 
on proteins. However, this might be at the cost of reducing the range of aberrant forms 
recognized. Contrary to this notion, the CPY and PrA ERAD determinants were 
observed to function flawlessly regardless of the perturbation. By contrast, other 
glycan sites, which would certainly have other functions, are generally incapable of 
signaling ERAD. 
 
By combining our findings with the recent studies of Aebi, Weissman and coworkers 
(Clerc et al., 2009; Quan et al., 2008), a detailed model of glycoprotein substrate 
recognition by the Hrd1p pathway was constructed (Figure 3.12). Following 
translocation from the Sec61p translocon and core glycosylation by oligosaccharyl 
transferase (OST), the nascent polypeptide begins the process of folding assisted by 
chaperones and folding catalysts. If the protein folds correctly, the glycopeptide 




Figure 3.12. Model of glycoprotein substrate recognition by the Hrd1p complex 
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Figure 3.12. Model of glycoprotein substrate recognition by the Hrd1p complex. 
Glycan processing by Gls1p, Gls2p, Mns1p and Htm1p are shown in the upper panel 
(Clerc et al., 2009). Lower panel: Polypeptide synthesis begins at membrane-bound 
ribosomes with translocation into the lumen via the Sec61p pore complex. The 
posttranslational translocation mechanism is not shown for simplicity. The substrate is 
N-glycosylated by the associated oligosaccharyl transferase (OST) and glycans are 
depicted as branched structures. Folding proceeds as chaperones (labeled "BiP"; other 
factors not shown for simplicity) engage the molecule. Molecules that correctly fold 
integrate ERAD determinants (red line) into the structure, silencing the signal and 
releasing BiP to allow export (left). Proteins that fail to fold are modified by Htm1p 
forming the glycan portion of the signal. BiP complexes bound to the ERAD 
determinant target to the Hrd1 complex at the ER membrane (right). Yos9p scans the 
substrate for the α1,6-mannose GlcNAc2Man7 structure. Molecules displaying the 
signal are retrotranslocated to the cytosol, ubiquitinated, and degraded by the 26S 




export signals (Figure 3.12, left). If the protein fails to fold by the time “mannose 
timer” enzymes convert the signal glycan to Man7GlcNAc2, the complex targets to the 
Hrd1p complex. BiP may play an active role in targeting since it can bind directly to 
the complex, probably through Yos9p (Denic et al., 2006). The glycan is likely not 
required for the targeting step since non-glycosylated CPY* associates with the Hrd1 
complex but not degraded (Denic et al., 2006; Gauss et al., 2006a). Yos9p scans for 
the terminal α1,6-mannose component of the Man7GlcNAc2 glycan. If present, the 
substrate is translocated across the membrane though an Sec61p retro-translocon pore 
(Schafer and Wolf, 2009). On the cytosolic face, the substrate is ubiquitinated through 
the concerted effort of Hrd1p and Ubc7p. The substrate is fully extracted from the 
membrane by the Cdc48p/Npl4p/Ufd1p complex and finally, degraded by the 26S 









Cellular quality control pathways monitor protein folding and target flawed products 
for turnover. In the secretory pathway, endoplasmic reticulum quality control (ERQC) 
mechanisms must also regulate trafficking to prevent the premature export of 
misfolded proteins. Proteins deemed misfolded are routed to ER-associated 
degradation (ERAD) pathways. These pathways are defined by specialized E3 
ubiquitin ligases that organize factors to receive and extract polypeptides from the ER 
membrane. On the cytosolic face, substrates are ubiquitinated and degraded by the 
26S proteasome (Romisch, 2005; Sifers, 2003; Sitia and Braakman, 2003; Vembar 
and Brodsky, 2008). 
 
In budding yeast, the Hrd1p and Doa10p ubiquitin ligases represent two distinct 
pathways (Carvalho et al., 2006; Huyer et al., 2004; Vashist and Ng, 2004). Clients of 
the Doa10p complex include folded cytosolic proteins and membrane proteins bearing 
misfolded cytosolic domains (ERAD-C) (Huyer et al., 2004; Metzger et al., 2008; 
Ravid et al., 2006; Swanson et al., 2001; Vashist and Ng, 2004). The complex 
organized around Hrd1p is termed ERAD-L because it detects misfolded luminal 
domains (Vashist and Ng, 2004). Besides luminal substrates, the Hrd1p complex also 
detects proteins with misfolded membrane segments through a mode termed 
ERAD-M (ERAD-membrane) (Carvalho et al., 2006). Together, these systems appear 
to account for the nascent polypeptides that traffic through the ER and provide a 
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unifying model for ERAD, at least in budding yeast (Carvalho et al., 2006). However, 
one distinct class falls outside the framework. A non-glycosylated variant of the 
mating pheromone precursor, ΔgppαF, is retained in the ER and degraded by the 
proteasome (McCracken and Brodsky, 1996). Unlike other known ERAD substrates, 
degradation is independent of ubiquitination and all known components of the E3 
complexes (Brodsky and McCracken, 1999). Cholera toxin and ricin A chain might 
hijack a similar ubiquitin-independent mechanism for its translocation from the 
ER-to-cytosol (Rodighiero et al., 2002; Simpson et al., 1999). By contrast, the 
mammalian Hrd1 pathway degrades unassembled immunoglobulin κ light chain and 
the NHK-QQQ variant of α1-antitrypsin, both non-glycosylated soluble proteins 
(Hosokawa et al., 2008; Okuda-Shimizu and Hendershot, 2007). Required 
components include Hrd1, p97 (Cdc48p in yeast), Derlin-1 (Der1p in yeast), Herp, 
and XTP3-B. In a mammalian cell-free system, ΔgppαF retrotranslocation does not 
require the activity of p97 but requires Derlin-1, a member of the Hrd1 complex 
(Wahlman et al., 2007). Do these findings indicate an evolutionary divergence of how 
this substrate class is degraded? 
 
In this chapter, Kazue Kanehara and I cooperated on the finding that the yeast Hrd1p 
complex has the capacity to process three substrate classes. The pattern of substrate 
specialization among components reveals functional modularity in its organization. At 
the most basic level is a core complex whose factors are required for all substrates. 
These are comprised of factors common to both Doa10p and Hrd1p complexes. The 
integration of accessory factors Usa1p and Der1p expands the client pool to include 
luminal proteins. The addition of another factor, Yos9p, adapts the complex to 
recognize misfolded glycoproteins vetted through a glycan timer mechanism. 
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Importantly, we demonstrate that utilization of luminal pathways is specified by 
signals embedded in proteins that are displayed only when misfolded. Together, these 
data show that the Hrd1p E3 complex manages distinct substrate classes by 




4.2.1. Novel PrA variants reveal a third substrate class of the yeast Hrd1p 
complex 
 
A folding defective mutant of the vacuolar proteinase A (PrA) called PrA*-Ab is a 
glycan-dependent substrate of the Hrd1p ERAD pathway (Finger et al., 1993; Spear 
and Ng, 2005). Deletion analysis identified two variants, PrA*-AbΔ147-183 and 
PrA*-AbΔ295-331, degraded rapidly with a reduced dependence on Htm1p, 
suggesting a glycan-independent mode of the Hrd1p complex (Figure 4.1) (Xie et al., 
2009). To confirm the assertion, a nonglycosylated variant called nonglycosylated 
PrA(ngPrA)*Δ295-331 was tested (Figure 4.2A). Its rapid degradation in control cells 
and stability in Δhrd1 cells demonstrate the existence of the pathway in budding yeast 
(Figure 4.2B). As expected, cells lacking HTM1 failed to retard its degradation and 
even slightly accelerated it (Figure 4.2B). For this pathway, the Δ295-331 lesion alone 
is sufficient to cause glycan-independent degradation of PrA. The variant 
ngPrAΔ295-331 (Figure 4.2A) that lacks the “star” deletion (amino acids 55-91) 
behaved identically (Figure 4.2C). Substrates of ERQC are typically retained in the 
ER even if degradation is blocked (de Silva et al., 1990; Gething et al., 1986; Loayza 









Figure 4.1. Specific PrA* variants bypass the Htm1p requirement for 
degradation. (by Kazue Kanehara) 
(A) Schematic representation of PrA variants with positions of deletions under each 
diagram. Carbohydrates are represented by branched symbols, signal sequences are in 
dark gray, pro-domains colored light gray and the positions of HA-epitope tags are 
shown. PrA* differs from PrA by lacking sequences Leu55 through Tyr91. 
(B) Wild type cells expressing PrA*-Ab, PrA*-AbΔ147-183, or PrA*-AbΔ295-331 
were pulse labeled for 10 min with [35S]-methionine/cysteine and followed by a cold 
chase for times indicated. Immunoprecipitations of substrate proteins were performed 
using anti-HA antibody and resolved by SDS-PAGE. Decay rates were quantified by 
phosphorimager analysis. The plotted data reflect three independent experiments with 
the SEM indicated. Representative gel images are shown to the left of each plot. 
(C) Wild type and Δhtm1 cells expressing PrA*-Ab were analyzed by pulse-chase 
analysis as described in panel B. 
(D) Wild type and Δhtm1 cells expressing PrA*-AbΔ295-331 were analyzed by 
pulse-chase analysis as described in panel B. 
(E) Wild type and ∆htm1 cells expressing PrA*-AbΔ147-183/295-331 were analyzed 







Figure 4.2. ngPrA variants are substrates of the Hrd1p complex 
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Figure 4.2. ngPrA variants are substrates of the Hrd1p complex. (by Kazue 
Kanehara) 
(A) Schematic representation of PrA variants with positions of deletions under each 
diagram. N-linked glycans are represented by branched symbols, signal sequences are 
in dark gray, pro-domains colored light gray, and HA-epitope tags are indicated. PrA* 
differs from PrA by lacking sequences Leu55 through Tyr91. 
(B) Wild type, Δhrd1, and Δhtm1 cells expressing ngPrA*Δ295-331 were pulse 
labeled for 10 min with [35S]-methionine/cysteine at 30℃, followed by a cold chase 
for the times indicated. Immunoprecipitation of ngPrA*Δ295-331 was performed 
using anti-HA monoclonal antibody and resolved by SDS-PAGE. Decay kinetics were 
quantified by phosphorimager analysis. The data reflect three independent 
experiments with the SEM indicated. Representative phosphor scan images are 
shown. 
(C) Wild type, Δhrd1, and Δhtm1 cells expressing ngPrAΔ295-331 were analyzed by 
pulse-chase analysis as described in panel B. 
(D) Intracellular localization of ngPrAΔ295-331 in Δhrd1 cells was analyzed by 
indirect immunofluorescence. The substrate was detected using anti-HA antibodies 
(green channel), the ER visualized using anti-Kar2p antisera (red channel), and the 




the ER marker BiP/Kar2p in Δhrd1 cells, confirming it as a bona fide substrate of 
ERQC (Figure 4.2D). 
 
To identify direct interactors of ngPrAΔ295-331, the substrate was purified from a 
microsomal fraction under nondenaturing conditions. A major species migrating near 
the 75-kD marker was identified as the ER chaperone BiP/Kar2p by mass 
spectrometry (Figure 4.3A and Table 4.1). To test the requirement of the chaperone in 
the glycan-independent mode of the Hrd1p pathway, ngPrAΔ295-331 turnover was 
analyzed in the kar2-1 and Δscj1Δjem1 mutants. The kar2-1 allele disrupts ERAD 
without affecting Kar2p’s essential housekeeping functions (Kabani et al., 2003). 
Scj1p and Jem1p are ER DnaJ family proteins that functionally interact with Kar2p 
(Nishikawa et al., 2001; Silberstein et al., 1998). Likely because of redundancy, SCJ1 
and JEM1 single mutants display weak and no ERAD phenotypes, respectively, 
whereas the double mutant is strongly defective (Nishikawa et al., 2001). 
ngPrAΔ295-331 is strongly stabilized in both strains, demonstrating a critical role of 
the chaperone system in glycan-independent ERAD (Figure 4.3B and 4.3C). 
 
4.2.2. The glycan-independent ERAD requires most but not all factors of the 
Hrd1p complex 
 
We next determined the factors of the Hrd1p complex required to recognize and 
degrade ngPrA∆295 -331. This is important because the accounting of ERAD factors 
required to recognize and degrade this substrate class remains incomplete (Hosokawa 
et al., 2008; Okuda-Shimizu and Hendershot, 2007). First, functions in common with 






Figure 4.3. The Kar2 chaperone is required for glycan-independent ERAD 
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Figure 4.3. The Kar2 chaperone is required for glycan-independent ERAD. 
(A) ngPrAΔ295-331 protein complexes purified from microsomes were resolved by 
SDS-PAGE and visualized by Coomassie Brilliant Blue. The band labeled “Kar2p” 
was excised and identified by mass spectrometry (Table 4.1). The asterisk indicates 
the position of IgG heavy chain. (by Kazue Kanehara) 
(B and C) Wild type, kar2-1, and ∆scj1∆jem1 cells expressing ngPrAΔ295-331 were 
analyzed by metabolic pulse-chase analysis as described in Figure 4.2B. The plotted 





Table 4.1. Peptide analysis of ngPrAΔ295-331-binding protein. (by Kazue 
Kanehara) 
 
The peptide sequences of Kar2p identified by mass spectrometry are summarized. 
Peptide position indicates the start and end point of the identified peptide within the 
sequence of Kar2p with the translation initiator methionine as position 1. Mr (expt) is 
the experimentally determined mass, and Mr (calc) is the calculated mass of the 
peptide. Delta represents the observed mass versus delta error. Miss indicates the 
number of missed trypsin cleavage sites, and the peptides identified column lists the 
actual sequence of the identified peptide. The ions score is -10*Log(P), where P is the 
probability that the observed match is a random event. Protein matches to NCBInr 
gi|6322426, Saccharomyces cerevisiae Kar2p. Nominal mass (Mr): 74480. 
 
Peptide position Mr (expt) Mr (calc) Delta Miss Peptides identified Ions score 
103–117 1,671.89 1,671.86 0.03 0 NQVAANPQNTIFDIK 24 
103–118 1,827.96 1,827.96 0 1 NQVAANPQNTIFDIKR ND 
135–143 1,066.61 1,066.59 0.02 0 HLPFNVVNK 17 
158–172 1,663.92 1,663.89 0.03 1 KVFTPEEISGMILGK ND 
185–201 1,887.01 1,886.96 0.04 0 VTHAVVTVPAYFNDAQR 26 
206–217 1,198.68 1,198.67 0.01 0 DAGTIAGLNVLR ND 
218–233 1,644.89 1,644.87 0.02 0 IVNEPTAAAIAYGLDK 32 
327–344 2,022.06 2,022.02 0.05 0 IEIDSFVDGIDLSETLTR 31 
345–356 1,465.8 1,465.78 0.02 1 AKFEELNLDLFK 16 
347–356 1,266.67 1,266.65 0.02 0 FEELNLDLFK ND 
375–387 1,344.7 1,344.69 0.01 0 DVDDIVLVGGSTR 25 
391–402 1,425.75 1,425.71 0.04 0 VQQLLESYFDGK ND 
391–403 1,553.83 1,553.81 0.02 1 VQQLLESYFDGKK 19 
467–484 2,022.06 2,022.05 0.02 1 KSQIFSTAVDNQPTVMIK ND 
468–484 1,893.99 1,893.95 0.04 0 SQIFSTAVDNQPTVMIK ND 
502–512 1,196.67 1,196.66 0.01 0 FELTGIPPAPR 21 
553–567 1,834.89 1,834.86 0.03 1 LTQEEIDRMVEEAEK ND 
83–95 1,512.74 1,512.71 0.03 0 ITPSYVAFTDDER 17 
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and Δcue1 strains indicating that its degradation follows a classical ERAD mechanism 
(Figure 4.4A and 4.4B). 
 
Next, genes encoding components exclusive to the Hrd1p complex were examined. 
Pulse-chase analysis shows that DER1 and USA1 are also essential for 
ngPrA∆295-331 degradation (Figure 4.4C). By contrast, degradation of 
ngPrA∆295-331 is efficient in a strain deleted of YOS9 (Figure 4.4D). This differs 
from glycan-dependent substrates, which depend heavily on Yos9p for degradation 
(Bhamidipati et al., 2005; Buschhorn et al., 2004; Kim et al., 2005; Szathmary et al., 
2005). Nevertheless, we did observe slight stabilization over wild type. Does this 
reflect a possible role in the glycan-independent pathway? In mammals, reduction of 
the Yos9p homolog hXTP3-B (long form) stabilizes the non-glycosylated NHK-QQQ 
substrate (Hosokawa et al., 2008). Alternatively, the effect could be indirect, caused 
structurally by physically eliminating a member of the complex. To confirm or rule 
out the latter possibility, we analyzed degradation in the yos9-R200A variant 
(Bhamidipati et al., 2005). In this strain, a conserved residue required for glycan 
recognition is mutated. By pulse-chase analysis, the degradation defect of PrA*-Ab 
(glycan-dependent substrate) yos9-R200A is equal to Δyos9, demonstrating the 
efficacy of the point mutation (Figure 4.4E). By contrast, ngPrA∆295 -331 turnover in 
the yos9-R200A was as efficient as wild type (Figure 4.4F). Taken together, the profile 
of ngPrA∆295-331 degradation mirrors that of misfolded glycoproteins except Htm1p 
and Yos9p are dispensable (Table 4.2). Although they are established mediators of 







Figure 4.4. ngPrA∆295-331 degradation requires multiple components of the 
Hrd1 complex. (by Kazue Kanehara) 
Metabolic pulse-chase experiments were performed and presented as in Figure 4.2B. 
Strains and substrates are indicated for each panel. 
(A) Wild type and cdc48-1 cells expressing ngPrA∆295-331 were grown to log phase 
at 25℃ and shifted to 30℃ for 30 min prior to the experiment. 
(B) Wild type and Δcue1 cells expressing ngPrA∆295-331. 
(C) Wild type, Δder1, and Δusa1 cells expressing ngPrAΔ295-331. 
(D) Wild type and Δyos9 cells expressing ngPrAΔ295-331. 
(E) Wild type, Δyos9, and yos9-R200A cells expressing PrA*-Ab. 




Table 4.2. Genetic requirements for the degradation of Hrd1p-dependent 
substrates. (by Kazue Kanehara) 
      Gene 
Substrate HRD1 CUE1 CDC48 USA1 DER1 YOS9 HTM1 
CPY*, PrA* + + + + + + + 
ngPrAΔ295-331 + + + + + － － 




4.2.3. ngPrA∆295-331 competes with the glycan-dependent substrate CPY* for 
degradation 
 
Previous studies provided evidence of Hrd1p subcomplexes, differing only by the 
occupancy of Yos9p (Gauss et al., 2006a). Combined with the data presented here, it 
raises the intriguing possibility of distinct receptor sites devoted to glycosylated and 
non-glycosylated substrates. We applied an in vivo substrate competition assay to test 
the possibility. CPY* regulated by the inducible GAL1 promoter was selected as the 
glycan-dependent competitor (Johnston and Davis, 1984; Knop et al., 1996b). Test 
proteins were constitutively expressed from their native promoters and turnover was 
monitored by metabolic pulse-chase analysis. As expected, CPY* competes with 
PrA*-Ab, the glycan-dependent control (Figure 4.5A). When the assay was applied to 
ngPrA∆295-331, a similar reduction was observed indicating that the two substrate 
classes do compete in ERAD (Figure 4.5B). To determine if competition is specific to 
the Hrd1p complex or includes general factors of ERAD, the assay was repeated with 
the Doa10p-dependent substrate Ste6-166p. Here, Ste6-166p degradation was as 
efficient as the negative control after a slight delay at the first chase point (Figure 
4.5C). These data show that the two luminal substrate classes can compete for the 
same Hrd1p complexes. 
 
4.2.4. The glycan-independent mode of Hrd1p pathway recognizes distinct 
degradation signals 
 
The classical ERAD substrates CPY* and PrA* contain bipartite degradation signals 






Figure 4.5. Glycan-independent and glycan-dependent substrates of ERAD are 
competitors for degradation 
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Figure 4.5. Glycan-independent and glycan-dependent substrates of ERAD are 
competitors for degradation. 
(A) Wild type cells carrying GAL1-regulated CPY* and PrA*-Ab regulated by its 
native promoter were shifted to galactose media to induce CPY* expression. Turnover 
of PrA*-Ab was analyzed as described in Figure 4.2B. (by Kazue Kanehara) 
(B) The experiment was performed as described for panel A with ngPrA∆ 295-331 as 
the test substrate. (by Kazue Kanehara) 





al., 2009; Quan et al., 2008; Xie et al., 2009). Without these glycans, the molecules 
are stable suggesting that the remaining segments are not recognized by a 
glycan-independent mode (Kostova and Wolf, 2005; Spear and Ng, 2005). To identify 
a glycan-independent determinant, we started with our shortest variant, 
PrA*-AbΔ147-183/295-331 (Figure 4.1E), and eliminated its remaining glycan to 
generate PrA*-GI (Glycan-Independent) (Figure 4.6A). As shown in Figure 4.6B, its 
degradation profile shows that it is a substrate of ERAD. A systematic deletion series 
was generated for PrA*-GI to identify essential ERAD determinants if they exist 
(Figure 4.6A). Deleting any of its three N-proximal segments had no effect on 
degradation (Figure 4.6C). This includes PrA*-GIΔ2 which eliminated the peptide 
portion of the glycan-dependent determinant (Xie et al., 2009). Deletion of the 
C-terminal segment, however, strongly stabilized the molecule indicating that an 
important element was altered (Figure 4.6C, PrA*-GIΔ4). 
 
By analogy to glycan-dependent signals, if the deletion specifically removed a 
degradation signal, PrA*-GIΔ4 is expected to be retained stably in the ER as a 
misfolded protein. Alternatively, mislocalization or the formation of a structure 
incompatible with ERAD could explain the phenotype. To address these possibilities, 
two experiments were performed. Indirect immunofluorescence shows that 
PrA*-GIΔ4 colocalizes with the ER marker BiP/Kar2p (Figure 4.6D). This result 
shows that the molecule is retained by ERQC, but incompetent for ERAD. To assess 
whether PrA*-GIΔ4 generated a molecule generally incapable of entering ERAD, the 
“A” glycosylation site was restored to reconstitute the original glycan-dependent 
signal. The resulting molecule, PrA*-GIΔ4CHO (Figure 4.6A) degraded rapidly in an 




Figure 4.6. PrA contains a distinct determinant for glycan-independent ERAD
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Figure 4.6. PrA contains a distinct determinant for glycan-independent ERAD. 
Substrate decay rates were measured and presented as described in Figure 4.2B 
(panels B, C, E, F, G). Strains and substrates are indicated for each panel. 
(A) Schematic representation of PrA*-GI variants. N-linked glycans are represented 
by branched symbols, signal sequences are shaded dark gray, pro-domains colored 
light gray and positions of HA-epitope tags are indicated. Dashed lines mark deleted 
regions. (by Kazue Kanehara) 
(B) PrA*-GI decay rates in wild type, Δhtm1, and Δhrd1 cells. (by Kazue Kanehara) 
(C) Degradation profiles for PrA*-GIΔ1, PrA*-GIΔ2, PrA*-GIΔ3 or PrA*-GIΔ4 in 
wild type cells. 
(D) Intraceullar localization of PrA*-GIΔ4 in wild type cells was analyzed by 
confocal microscopy. The substrate was detected using anti-HA antibodies (green 
channel), the ER was visualized using anti-Kar2p antisera (red channel), and nuclei 
are stained by DAPI. Scale bar, 5 µM. 
(E) Wild type and Δhtm1 cells expressing PrA*-GIΔ4CHO. 
(F) Wild type, Δhrd1, Δusa1, and Δder1 cells expressing PrA-CTD. (by Kazue 
Kanehara) 




lesion eliminated a critical degradation signal. To determine if the element is sufficient 
to signal glycan-independent degradation, the C-terminal domain (CTD) containing 
this domain was expressed immediately on the C-terminus of the PrA signal sequence 
(Figure 4.6A, PrA-CTD). The non-glycosylated PrA-CTD is degraded rapidly in wild 
type cells and strongly stabilized in Δhrd1, Δusa1, and Δder1 strains, confirming that 
it uses the Hrd1p pathway (Figure 4.6F). As expected, PrA-CTD degradation is 
efficient in cells lacking HTM1 or YOS9 (Figure 4.6G). This result confirms that the 
Hrd1p complex can efficiently process non-glycosylated luminal substrates in the 
absence of Yos9p. These data show that determinants recognized by the 
glycan-dependent and glycan-independent modes of the Hrd1p complex can be 




This study extends the known Hrd1p client range in budding yeast and demonstrates 
that the surveillance of both luminal substrate classes by the Hrd1p complex is 
conserved. From these results came the question of how a single complex manages 
such a diverse range of substrates. By compiling data of previous reports and those of 
this study, an interesting pattern emerges (Table 4.2). Misfolded membrane substrates 
like Sec61-2p and Hmg2p have the simplest requirements. These include the 
Hrd1p/Hrd3p E3 dimer, the E2 dimer Cue1p/Ubc7p and the AAA ATPase subcomplex 
Cdc48p/Npl4p/Ufd1p/Ubx2p (Bays et al., 2001b; Carvalho et al., 2006; Sato et al., 
2009). These components, interchangeable between the Hrd1p and Doa10p complexes, 
are required for all ubiquitin-dependent substrates thus far. Adding Der1p and Usa1p 
in the complex expands the Hrd1p range to handle luminal substrates bearing specific 
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peptide signals. The additional presence of Yos9p endows the capacity to recognize 
glycan signals marking substrates whose time windows for folding have expired 
(Clerc et al., 2009; Quan et al., 2008). 
 
The primary functions of ERAD E3 complexes include substrate sorting, 
ubiquitination, and extraction. By extension, the Hrd1p core complex must be 
sufficient to carry out these activities for recognition and degradation of membrane 
substrates. Recently, a systematic study revealed that Hrd1p transmembrane segments 
detect structural deviations in substrate transmembrane domains (Sato et al., 2009). 
This suggests that Hrd1p itself recognizes degradation signals for this class. With the 
source of ubiquitination and substrate extraction activities already known, this study 
explains why components outside the core are dispensable for this class. The 
accessory factors Der1p and Usa1p are required for all substrates of the Hrd1 pathway 
bearing luminal lesions (Figure 4.4C) (Carvalho et al., 2006; Knop et al., 1996a). 
Their inclusion is sufficient for the Hrd1p complex to process luminal substrates 
bearing glycan-independent determinants. Although their precise roles in ERAD 
remain unclear, the prevailing evidence suggests that they facilitate the movement of 
luminal domains to the cytosol. The mammalian Der1 homolog Derlin-1 is in 
proximity to MHC class I molecules during retro-translocation across ER membranes 
(Lilley and Ploegh, 2004; Ye et al., 2004). This makes Derlin-1 a candidate 
component of the ERAD translocation pore. Although a role in signal recognition is 
not ruled out for Der1p and Usa1p, Hrd3p more likely plays this role in ERAD in 
addition to Yos9p. Hrd3p binds misfolded CPY* with or without its glycans (Gauss et 
al., 2006a). Thus, Hrd3p is the best candidate as the substrate receptor for the 
glycan-independent luminal pathway. The further addition of Yos9p adapts the 
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complex to recognize glycan-dependent substrates (Bhamidipati et al., 2005; 
Buschhorn et al., 2004; Kim et al., 2005; Szathmary et al., 2005). Their requirement 
for Der1p and Usa1p indicate that both luminal substrate classes share the same 
processing mechanism after recognition. It is therefore not surprising that the 
pathogenic protein cholera toxin has coopted this pathway for its cytosolic entry from 
the ER (Bernardi et al., 2008). Taken together, the Hrd1p core complex exhibits 
remarkable functional plasticity. The addition of three accessory factors, Der1p, 
Usa1p, and Yos9p, is sufficient to expand its client range from a one class to three. 
This theme is expanded in the mammalian system. The Yos9p homologs OS-9, 
XTP3-B, and their variants display substrate specificities that may be used to further 
diversify the substrate range (Christianson et al., 2008; Hosokawa et al., 2008). 
 
One of the longstanding questions of ER quality control revolves around the 
molecular cues used to differentiate folded, actively folding, and terminally misfolded 
proteins. It is now well established that glycoprotein substrates can display highly 
specific signals for degradation. Normally, N-linked glycans of nascent polypeptides 
are progressively trimmed in the ER by GI, GII, and Mns1p to the Man8GlcNAc2 
structure. Should a molecule fail to fold at this point, the Htm1p mannosidase cleaves 
a single residue to expose a terminal α1,6-linked mannose, the ligand for the Yos9p 
receptor (Clerc et al., 2009; Quan et al., 2008). This combines with adjacent 
disordered peptide segments to form a bipartite ERAD determinant (Chapter 3, Xie et 
al., 2009). PrA may form a class of substrates that harbor determinants for both modes 
of the Hrd1 complex. Our analyses show that the PrA glycan-independent determinant 
is located in a region distinct from its glycan-dependent determinant (Figure 4.6). 
These studies show that ERAD does not perceive the general “foldedness” of proteins 
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but responds to specific cues in substrates that coevolved with the system. This might 
explain why yeast and mammalian ERAD pathways are sometimes unable to 
recognize misfolded proteins from other organisms (Coughlan et al., 2004; Hong et al., 
1996; Mancini et al., 2003). This suggests that although much of the general 
mechanisms are conserved, the specific nature of some signals may have diverged. 
 
The novel PrA variants demonstrate the conservation of the ubquitin-proteasome 
system in the quality of control of soluble non-glycosylated proteins. Our studies are 
consistent with the current understanding of how this class is processed by the 
mammalian Hrd1p pathway (Hosokawa et al., 2008; Okuda-Shimizu and Hendershot, 
2007). Therefore, it is likely that the advancements represented by this study are also 
applicable to mammals. The discovery of the glycan-independent mode of the Hrd1p 
complex also shows that budding yeast have at least two distinct mechanisms for 
soluble, non-glycosylated substrates, one ubiquitin-dependent and another 
ubiquitin-independent (Nakatsukasa and Brodsky, 2008). Although not fully 
characterized, there are indications of a similar arrangement in mammals. Evidence of 
a mammalian ubiquitin-independent mechanism comes from detailed analysis using 
an elegant cell-free system. In this assay, the yeast ΔgppαF substrate undergoes 
retro-translocation across ER membranes independently of ubiquitination and p97 (the 
Cdc48p ortholog) (Wahlman et al., 2007). This result indicates that the structural cues 
used to sort this substrate in yeast are faithfully recognized in mammals and 
strengthens the view that ERQC mechanisms use specific determinants embedded in 
substrates to signal degradation if misfolded. 
 
The ERAD client portfolio is perhaps the most varied among quality control systems. 
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To tackle the challenge, substrate receptor sites have evolved to handle the topological 
diversity of substrates. It is now clear that the clearance of defective molecules is due 
to signals embedded within the substrates themselves. Molecules not bearing features 
recognized by ERAD, but are nevertheless misfolded, are handled by alternative 
pathways. Some use ubiquitin-independent mechanisms of ERAD, others are sent to 
the vacuole (the yeast lysosome) through autophagy or via the classical secretory 
pathway (Chang and Fink, 1995; Hong et al., 1996; Jenness et al., 1997; Kruse et al., 
2006; Ravikumar et al., 2002; Sarkar et al., 2007; VanSlyke et al., 2000). 
Understanding how these molecules are differentiated from folded proteins remains a 




Conclusions and future directions 
 
Stringent quality control and efficient degradation of misfolded proteins in the ER 
ensure cellular functions are executed with no or minimum perturbations, therefore 
are crucial to cells. Proteins of various classes (glycoproteins, non-glycosylated 
proteins, and membrane proteins) trafficking through the secretory pathway requires 
ERQC and ERAD to be able to detect all kinds of lesions. 
 
In recent years, much progress has been made in understanding the molecular 
components of ERQC and ERAD and their substrate recognition in both yeast and the 
mammalians. This thesis uses budding yeast as a model system and provides 
important findings in the mechanisms of protein folding quality control in the ER 
lumen. 
 
Quality control of glycoproteins in the ER 
 
Pre-assembled glycans are attached on newly synthesized proteins while they are still 
in the translocon pore. In mammalian cells the CNX/CRT cycle acts as the first stage 
of quality control for N-linked glycoproteins, whereas in yeast the lack of CNX/CRT 
cycle makes Mns1p the first stage by acting as a molecular timer. The “mannose 
timer” hypothesis states glycoproteins entering the ER are allowed a time window to 
fold by the trimming action of Mns1p, afterwhich those haven’t complete folding will 
be seen by ERQC as misfolded proteins and degraded by ERAD. To strengthen the 
hypothesis, two other luminal factors, Htm1p and Yos9p, are later found to provide 
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function downstream of Mns1p and essential for ERAD (Clerc et al., 2009; Quan et 
al., 2008). Htm1p is also an ER mannosidase, it specifically removes an α1,2-linked 
mannose residue to expose the high affinity binding ligand for the ER lectin receptor 
Yos9p. But the hypothesis cannot explain why in glycoproteins with multiple 
N-glycans, only a single one is both necessary and sufficient for ERAD whereas all 
the other ones are dispensible (Kostova and Wolf, 2005; Spear and Ng, 2005). 
 
The findings in Chapter 3 of this thesis provide insights into the mechanism for 
ERQC of glycoproteins. I have dissected misfolded substrates and revealed the nature 
of the bipartite signal for ERAD – disordered polypeptide surrounding an N-linked 
glycan. Residing in the last folded segment of the polypeptide, the bipartite signal is 
usually buried into the tertiary structure of a folded glycoprotein therefore undetected 
by ERQC and ERAD. Should the protein misfold, the bipartite signal will remain 
disordered and exposed to ER chaperone BiP/Kar2p. In this way it acts like a sensor 
to report the overall folding state of the glycoprotein to the Hrd1p complex. 
 
With these findings, we now have a more clear understanding on substrate recognition 
by the Hrd1p complex and its luminal cofactors (Mns1p/Htm1p/Yos9p/Kar2p). First 
of all, Mns1p provides a time window to all newly synthesized glycoproteins entering 
the ER lumen by marking the glycans Man8GlcNAc2 (Jakob et al., 1998a). And on the 
protein itself, the bipartite determinant remains exposed to chaperone Kar2p unless 
the entire molecule is completely folded (Xie et al., 2009). Second, Htm1p trims the 
glycans further down to Man7GlcNAc2 with with α1,6-linked mannose residue 
exposed on branch C (Clerc et al., 2009). At last, given Yos9p interacts directly with 
the Hrd1p complex through Hrd3p (Denic et al., 2006), it is very likely to act as a 
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proofreading receptor lectin by scanning the substrate’s glycan structure, and 
delivering the right ones to the Hrd1p complex for degradation (Quan et al., 2008). 
However, it is currently unknow whether Htm1p scans and trims all the N-glycans 
present on glycoproteins, or it selectively processes the particular N-glycan of the 
bipartite signal. Although results from oligosaccharide assembly mutant Δalg3 have 
favored the latter speculation, further study is needed to provide direct evidences to 
prove it. 
 
Quality control of non-glycosylated proteins in the ER 
 
Another class of proteins exists in the ER lumen lacking N-linked glycans, and there 
have been reports of several non-glycosylated substrates subject to ERQC and ERAD 
through the Hrd1p pathway in both yeast and mammalian cells. Compared with 
glycoproteins, the mechanism for their quality control is largely unknown. 
 
Chapter 4 of this thesis has revealed mechanistic insight into the glycan-independent 
track of Hrd1p pathway. Quality control of non-glycosylated substrates requires all 
glycan-dependent Hrd1p pathway components such as chaperones and the UPS, 
except mannosidase Htm1p and lectin receptor Yos9p. And a distinct degradation 
signal near the C-terminus was found to be necessary and sufficient to target the 
glycan-independent Hrd1p pathway. 
 
Interestingly, substrates from both glycan-dependent and independent pathways 
compete for the same Hrd1p complex, suggesting a single complex capable of 
detecting three classes of misfolded substrates (membrane, glycosylated and 
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unglycosylated). The underlying mechanism can be revealed by compiling recent 
discoveries in yeast. First, the core complex, including Hrd1p/Hrd3p E3 dimer, 
Cue1p/Ubc7p E2 dimer and Cdc48p/Npl4p/Ufd1p/Ubx2p complex, is inherently able 
to bind and detect membrane substrates (Sato et al., 2009). Together they provide a 
membrane scaffold for additional factors. Second, with a membrane module consists 
of Der1p and Usa1p added to the core, the Hrd1p complex now expands its client pool 
to ER lumen. Then a luminal mannosidase-lectin receptor module 
(Mns1p/Htm1p/Yos9p) is recruited to enable the full complex to deal with even subtle 
structure pertubations in glycoproteins (Clerc et al., 2009; Quan et al., 2008; Xie et al., 
2009). Although non-glycoproteins utilize signal embedded in themselves for their 
quality control, similar as glycoproteins, the mechanism for how this 
glycan-independent signal is presented to the Hrd1p complex is still unknown 
therefore awaits further investigation. 
 
Collectively, work described in this thesis provides an understanding of the quality 
control and degradation of misfolded proteins in the ER lumen. It will be interesting 
to see if the findings gained from this study could help decipher the ERQC 
mechanism in more detail and if they are also applicable to the quality control 
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